

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 September 2002 (06.09.2002)

PCT

(10) International Publication Number
WO 02/067853 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: **PCT/US02/02480**
- (22) International Filing Date: 26 January 2002 (26.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|----------------|-------------------------------|----|
| 60/264,511 | 26 January 2001 (26.01.2001) | US |
| 60/264,504 | 26 January 2001 (26.01.2001) | US |
| 60/307,689 | 25 July 2001 (25.07.2001) | US |
| 09/912,703 | 25 July 2001 (25.07.2001) | US |
| PCT/US01/31328 | 6 October 2001 (06.10.2001) | US |
| 09/997,490 | 17 November 2001 (17.11.2001) | US |
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- | | |
|----------|-------------------------------|
| US | 60/238,504 (CIP) |
| Filed on | 6 October 2000 (06.10.2000) |
| US | 60/238,506 (CIP) |
| Filed on | 6 October 2000 (06.10.2000) |
| US | 60/243,901 (CIP) |
| Filed on | 27 October 2000 (27.10.2000) |
| US | 60/243,902 (CIP) |
| Filed on | 27 October 2000 (27.10.2000) |
| US | 60/245,592 (CIP) |
| Filed on | 17 November 2000 (17.11.2000) |
| US | 60/264,511 (CIP) |
| Filed on | 26 January 2001 (26.01.2001) |
| US | 60/264,504 (CIP) |
| Filed on | 26 January 2001 (26.01.2001) |
| US | 60/307,689 (CIP) |
| Filed on | 25 July 2001 (25.07.2001) |
| US | 09/912,703 (CIP) |
| Filed on | 25 July 2001 (25.07.2001) |
| US | 09/997,490 (CIP) |
| Filed on | 17 November 2001 (17.11.2001) |
| US | PCT/US01/31328 (CIP) |
| Filed on | 6 October 2001 (06.10.2001) |
- (71) Applicant (for all designated States except US): **PRO-BIOCHEM, LLC** [US/US]; 326 Hedgepocket Way, Reisterstown, MD 21136 (US).
- (71) Applicants and
- (72) Inventors: **KINDNESS, George** [GB/US]; 7207 Stonebrook Ct., Middletown, OH 45044 (US). **SCHUMM, Brooke, III** [US/US]; 2813 Thornbrook Road, Ellicott City, MD (US). **GUILFORD, Timothy, F.** [US/US]; 829 Forest Ave., Palo Alto, CA (US).
- (74) Agent: **SCHUMM, Brooke, III**; Daneker, McIntire, Schumm et al, Suite 800, 210 N. Charles St., Baltimore, MD 21201 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A COMBINATION AND METHOD OF TREATMENT OF HIV AND VIRAL DISEASES, VASCULAR DISEASE AND CANCER UTILIZING A COX-2 INHIBITOR AND CYSTINE

(57) Abstract: The inventors propose the combination of a selective COX-2 inhibitor and cystine first, for the treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C; second, for the treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems (atherosclerosis and these latter problems collectively referred to as "vascular-associated disease"), third, for the treatment of cancer and fourth, to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia. An HMG-CoA reductase inhibitor may be added to enhance the combination. Magnesium sulfate or similar compound is proposed to be added to enhance the treatment of neurodegenerative conditions.

WO 02/067853 A2

A COMBINATION AND METHOD OF TREATMENT
OF HIV AND VIRAL DISEASES, VASCULAR DISEASE AND CANCER
UTILIZING A COX-2 INHIBITOR AND CYSTINE

CONTINUATION DATA

For purposes of priority and continuation, this is a continuation-in-part of Provisional Application No. 60/264,504 entitled "A Combination and Method of Treatment of HIV and Viral Diseases, Vascular Disease and Cancer Utilizing a COX-2 Inhibitor and Cystine," filed January 26, 2001, which referenced and incorporated 60/264,512 filed in the United States of America on January 26, 2001 entitled "A Composition and Method of Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent preferably Using Selective Cox-2 Inhibitor and HMG-CoA Reductase Inhibitor" and Provisional Application 60/264,511 entitled "A Combination and Method of Treating of Cancer Utilizing an additional COX-2 Inhibitor Etoricoxib and a 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Inhibitor and Cystine to Enhance Glutathione Function" also filed in the United States of America on January 26, 2001. It is also a continuation-in-part of provisional Application 60/279,008 entitled "A Combination and Method of Treatment of Neurogenerative Diseases Aggravated by Inflammation 5-HT Mediated Mechanisms and Migraine, filed on March 27, 2001. This is also a continuation in part from Appl. 60/307,689 and Utility Application 09/912,703 both filed July 25, 2001, and PCT US01/31328 entitled "A Combination and Method of Treatment of Cancer Utilizing A COX-2 Inhibitor etoricoxib and a 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor" and a provisional application and Utility Application filed in the U.S. November 17, 2001 No. 09/997,490, and a provisional application filed this day of this name, which provisional applications and utility application and

other application(s) are incorporated by reference and priority claimed from them.

SUMMARY OF INVENTION

The inventors propose a combination of a selective COX-2 inhibitor, and cystine. The proposed efficacy is first, for the treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C; second, for the treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems (atherosclerosis and these latter problems collectively referred to as "vascular-associated disease"), third, for the treatment of cancer and fourth, to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia. The inventors propose a method of treatment by the use of a selective COX-2 inhibitor alone of anti-viral diseases, including HIV, AIDS and hepatitis C, of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems, of cancer and of treatment of 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia. The latter group of 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and neurodegenerative diseases aggravated by inflammatory condition and carotidynia will all be collectively referred to as "neurodegenerative conditions." Methods to

accomplish those proposed efficacies of administration of the substances referenced are claimed, and for more than one substance, stepwise or in combination. The method of manufacturing any two or more of the substances together is claimed. The reference to human biochemistry is not intended to be limiting, but illustrative, as the invention is applicable to mammals. The inventors propose the addition of cystine (as later defined) to the compounds and methods set forth in the Winokur and Nichtberger art for the objects and purposes therein because of the effect of cystine on the glutathione pathway, and the additional and cooperative anti-inflammatory effects.

Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease" claims a combination of a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events and a method of using a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events. Another patent, Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled "Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions" proposes the utilization for an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor to treat, prevent or reduce the risk of acute coronary ischemic syndrome, thrombosis, and related vascular problems. Waldstreicher, WO 01/45698, filed 18 December 2000, published June 28, 2001 entitled "Combination Therapy for Treating Neurodegenerative Disease" proposed treatment of neurodegenerative diseases with a selective COX-2 inhibitor and an HMG-CoA inhibitor. The inventors propose the addition of cystine to a selective COX-2 inhibitor only in order to enhance its anti-inflammatory effect and to

moderate the potential negative effects of a COX-2 inhibitor, particularly negative gastrointestinal effects, negative liver effects or negative kidney effects. The term patient or body or reference to humans is utilized for convenience, but includes all mammalian patients or bodies. The inventors propose to use a selective COX-2 inhibitor alone, though less efficacious than in combination with cystine, first, for the treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C; second, for the treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems (atherosclerosis and these latter problems collectively referred to as "vascular-associated disease") and third, for alleviation of 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia. An HMG-CoA reductase inhibitor or statin could also be added.

BACKGROUND FROM RELATED APPLICATIONS:

Incorporated by reference into this application is a Provisional Application filed on January 26, 2001 entitled "A Composition and Method of Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent Preferably Using Selective COX-2 Inhibitor and HMG-CoA Reductase Inhibitor" and Provisional Applications cited therein including Provisional Application 60/249,592 filed November 17, 2000 entitled "A Combination and Method of Treatment of Cancer Utilizing a COX-2 Inhibitor and an HMG-CoA Reductase Inhibitor and Cystine.

Background:

Traditional cancer treatments have generally used an approach which is focused on directly attacking cells with a propensity to divide. The cancer cell is viewed as a bad cell that must be eliminated. The methods and combinations chosen focus on destruction of the dividing cell, or chemical attack of the cell.

This invention proposes a different methodology. The first premise is to recognize the highly adaptable characteristics and durable biochemistry of the cancer cell from a biochemical and genetic viewpoint. Many cancer cells are body cells gone awry. The literature solidly suggests that cancer cells in a patient's body have a capability to readapt their functions to adjust to ambient conditions. A patient's body also has an impressive capability to adapt to changing macro-environmental conditions, as well as the micro-environmental conditions in biological chemistry internal to the cell.

Cancer cells, in a genetic or evolutionary sense, are not "bad" cells. Rather, they are efficient cells; in fact, they are highly efficient cells in a certain way. They use relatively less oxygen for the total amount of activity they undertake, and they divide rapidly, enabling them by normal processes of mutation and evolution to adapt their genetic material more quickly. Were the systems and cells in the rest of our bodies equally efficient, we would be greater evolutionary giants than we stand today.

For any attack on cancer cells to be successful, unless they can be physically cut out of the body by surgery, the attack cannot be "too successful." Cancer cells are us, and in a much slower evolutionary way, we are cancer cells. Too much success in damaging cancer cells pharmacologically in the prior art has often been destructive of the host body.

Returning to and illustrating the principle that the body is one large biochemical machine, suppose drops of salt water with colored salt are added to a larger volume of pure water in a container. The body is close to 98% seawater, meaning traditional H₂O water with many other substances and compounds floating in the water. At first the drops would appear whole, but gradually the drops would dissipate so that the entire container might take on a tinge of color. The salt would be dispersed throughout the container so that, once equilibrium was established, all parts of the container had an equal concentration of the salt for each small volume of water.

Before that equilibrium was established, the drops of colored water carrying the salt would tend to flow from areas of higher concentration (such as the original drops) to areas of lower concentration in the container (such as the "corners" of the container where there was originally no colored water. That tendency to flow from areas of greater concentration to lesser concentration calls for a resolution of osmotic imbalance generating a pressure gradient and is very important to understanding this invention.

Our bodies are not however, a mere blob of water without structure. Cells are a packet of "sea water" with many compounds in the water surrounded by a membrane. Just like a pile of wet sand full of water will not hold its shape for building a sand castle, but is very strong and can form a formidable dike if the wet sand is in a bag, the contents of cells in a body, surrounded by a membrane, give the body of humans its structure. Metaphorically, human beings are a standing milieu of tiny piles of sea water in bags called membranes.

On a microscopic scale, the body acts the same way as the earlier described container of salt water. Drops in the form of minute or low concentrations of biologically significant chemicals gradually diffuse throughout our body through links from the membrane bags of sea water in systems of pipes called blood and lymph vessels. Taking advantage of differences in concentration, the blood vessels biochemically "transport" substances either to cells or from cells. Within cells, biochemicals travel by osmosis affected and influenced by biochemical cycles. When cells are short of glucose, the basic fuel product of food, cells have a lower concentration of a substance they need, and if there is a higher concentration of glucose in an adjacent capillary which has a blood cell, some of that glucose flows across the membrane in a complicated biochemical transport mechanism to restore the concentration of glucose in the cell, naturally depleting the concentration in the blood stream.

To complicate the picture in the body context, not all membranes allow all substances to pass. Some are only semi-permeable, allowing only compounds in certain shapes or sizes to pass. For those semi-permeable membranes, if the concentration of compounds on one side of the membrane changes, for instance, increases, then water will flow to that side of the membrane to re-balance the concentration.

Relying on the premise that cancer cells need to divide or replicate (since if they are stable they either pose less danger or are gradually eliminated), the invention takes advantage of that tendency of cancer cell's needs which cause chemicals to flow from areas of greater concentration to those of lesser concentration. First, cancer cells need energy in order to do what they do the most and best, which is to divide or replicate. Energy in a cell is provided by the Krebs cycle. Cancer cells, because they divide frequently, are very sensitive to interference with their energy processes.

Second, when any cell divides, including cancer cells, the bag around the cell which is the membrane has to split into two bags. This presents two problems for the cancer cell. One, the cancer cell needs relatively more cholesterol in order to replicate successfully than a normal cell needs for its normal activities. Two, the membrane is necessarily weakened somewhat as the dividing process occurs and the cell transforms from one cell into two cells like a sandwich being pulled apart into two halves.

The human body is not completely helpless against inflammatory processes, viruses cancers. However, viruses and cancer cells are relatively good at deceiving or confusing the immune system of our body into believing that the virus or cancer cells are not as bad as they really are, or alternatively, because of rapid replication and evolution, developing defenses against the immune system. Further, as a virus or cancer progresses, it damages the body's immune system, including by triggering long-term inflammatory mechanisms.

In total, this invention proposes to use a novel combination to inhibit key biochemical cycles in a way that causes more damage to the cancer cell than to other cells, to decrease long-term inflammation, and to improve and sustain the body's immune system so it can better attack the weakened cancer cells and support the body's remaining essential functions. The inventors propose to selectively modify several biochemical pathways so as not to destroy overall body function, but disproportionately harm cancer cells, to enhance the body's immune system in order that the immune system may attack the cancer cells, and by stressing the cancer cell, to inhibit the cancer cell's normal resistance to immune system function, and to protect the body's normal cells.

The inventors propose a method of treatment of cancer, particularly prostate cancer and pancreatic cancer, by a particular combination of drugs for that purpose which has not been previously proposed for that purpose. The inventors propose a method of treatment of cancer involving a novel combination of drugs which simultaneously slows the cancer but also enables the body's immune system to better attack or fend off the cancer.

The first object of this invention proposes to selectively interfere with the production of cholesterol in two places in a way that impairs the energy cycle of all cells but which normal cells can overcome because they need less energy to survive because they are not dividing, but in a way that has a disproportionate and damaging effect on cancer cells which must replicate, or the cancer will not spread. This object takes advantage of the cancer cell's requirement for cholesterol causing biochemical signaling for cholesterol if not adequate to meet the replicating cancer cell's needs.

A second object is to selectively modify a biochemical cycle that targets inflammatory mechanisms in the body. One of the most damaging aspects of cancer cells is that they trigger an extended inflammatory response in the body. Further, as cancer progresses, it damages the body's immune system by a number of mechanisms, including the triggering of an extended inflammatory response in the body, which is less efficient in the removal of cancers. Prostaglandins are some of the most important signals to cause inflammatory responses. The biochemical cycle that we propose to selectively inhibit is an important cycle that converts arachidonic acid to several forms of prostaglandins. That cycle is the cyclooxygenase or COX cycle.

Biochemical cycles have many intermediate steps in them and the intermediate compounds are known as "intermediates." One of those intermediates in the cyclooxygenase cycle is prostaglandin H2 synthase, which has two forms: COX-1 and COX-2. COX-1 is known as a housekeeping substance which helps generate substances that protect the stomach. Ding et al, "Blockade of Cyclooxygenase-2 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells, vol. 20 AntiCancer Research, 2625-2632 (2000). Aspirin inhibits COX-1 and therefore, because it inhibits a substance that protects the stomach, often has gastrointestinal side effects. Recently, substances have become available that selectively inhibit

COX-2 enzymes over COX-1 enzymes. COX-2 enzymes regulate pain, inflammation and fever, i.e. inflammatory mechanisms.

The COX-2 inhibitors in this invention interfere with the transformation of a substance called squalene to cholesterol. There are numerous intermediates from squalene to cholesterol.

Earlier in the biochemical cycle that produces cholesterol is a substance called Acetyl-CoA enzyme. It is converted to an intermediate called mevalonate by an enzyme called 3-hydroxy-3-methylglutamate-CoA reductase ("HMG-CoA"). Recent pharmaceutical advances have produced a number of substances that inhibit the activity of HMG-CoA and slow the production of cholesterol. HMG-CoA inhibitors have been used and are claimed to be used to reduce cholesterol to slow various blood vessel and related heart disease problems which we generally refer to as cardiovascular disease.

A third object of this invention is to utilize the more optimal function of cystine in the pH balance of a normal cell than in the lower pH of a cancer cell. The administration of cystine, enhances the body's immune system benefitting the total body disproportionately to any benefit cystine administration may have for a cancer cell.

In sum, the premise of this invention is that the cancer cells divide rapidly, that they have significant anaerobic glycolytic processes, and that the body is one large biochemical machine in which we can play to the strength of our body to the detriment of the cancer cell.

The science behind the combination is based on a triad of attacks on the biochemical pathways contributing to cancer cell replication.

Cancer cells must necessarily replicate for a "cancer" to thrive. Attacks on biochemical cycles at points where replication are involved are a favored approach. Cancer cells are particularly vulnerable to interference with lipid cell membrane status and ATP synthesis.

The COX-2 inhibitor interferes with the operation of the cyclooxygenase cycle from which are generated prostaglandins critical in cell division chemistry, and inhibits the "long-term" effects of inflammatory effects. Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (November 2000).

Tumors and their malignant cancer cells multiply in an exponential growth pattern relative to other body cells. Any retardation of replication will have an exponential effect in slowing cancer growth. Any apoptosis of a cancer cell has a disproportionately exponential effect in retarding cancer. Current treatments such as chemotherapy and radiation therapy which have severe quality of life effects have relied on this disproportionately exponential effect to achieve what benefits those treatments do achieve for extending the life of patients.

This invention has the further benefit as distinct from prior art of accomplishing its benefits with substantially less interference with quality of life than chemotherapy and radiation therapy(ies) in particular.

Subsequent to earlier provisional applications, a citation is made in Drug Facts and Comparisons, 55th ed. 2001 at KU-16 (Publ. by Facts & Comparisons 2000) to a pending trial of Ubiquinone under a trade name of Ubigel by Gel-Tec. Ubiquinone or CoQ-10 administration is not likely have the benefits of the present invention because it is proposed to be administered by macroadministration to the entire organism, either orally or intravenously or in the general vicinity of the tumor area.

By contrast to such effort at macroadministration, this invention as proposed in the prior provisional application proposes virtual microadministration. This is a unique aspect of this invention and an important concept behind the invention. The inventors propose that one of the dilemmas of cancer therapy is to deliver the needed dose to the right place and minimize harm when the therapy is not in the right place.

The inventors believe that the most optimal treatments involve the utilization of the biochemical physiologic machine of the body, and preferably of the individual cell, to construct, manufacture and adjust the individual cell chemistry to achieve the desired object: in the case of the cancer cell or other afflicted and undesired cell, to disrupt its mechanisms of replication, primarily by focusing on the energy mechanism of the cell with the corollary result of interfering with membrane synthesis and cell replication, and in many instances, as the cell struggles to reach homeostasis, inducing apoptosis. Simultaneously, the remaining desired and normal cells must be reinforced to meet the threat of the cancer and to resist the side effects of the treatment that interfere with normal cell operation, which is why cystine, in addition to its increase in TH1 to Th2 ratio, achieves notable benefit despite literature suggesting to the contrary. See, for example, "Clinical Oncology" (Amer. Cancer Society 2001) at 186 (discourages medical practitioners from glutathione pathway enhancement); Volies and Golomb, "Oncological Therapies" (Springer 1999) at 126 in the selection by Ratain, Ewe, Suede, entitled Cancer Chemotherapy at 36-100. As another example, one of the clear benefits of the selective COX-2 inhibitor is that COX-1 isoenzymes have what has been characterized as general housekeeping functions generally ameliorative to bodily health. Aspirin, a classic COX-2 inhibitor, also inhibits COX-1, thereby achieving anti-inflammatory effect, for which aspirin is well-known, at the cost of beneficial aspects of COX-1 isoenzymes. Thus, a selective COX-2 inhibitor is important in the invention.

Lipoic acid can be an adjunct to cystine in the invention. Lipoic acid also has a disulfide bond as does cystine. That disulfide bond can be separated and the sulphur protonated with hydrogen. Thus, lipoic acid can reinforce the benefits of cystine. For instance, a ras oncogene generates a ras protein. "The transforming (carcinogenic) activity of the ras oncogene is lost when isoprenylation of the Ras protein is blocked, stimulating interest in identifying inhibitors of this postranslational modification pathway for use in cancer chemotherapy." Nelson, Cox, Lehninger Principles of Biochemistry at 1054 (3rd ed. 2000 Worth Publishers). Because the same thiol group on a Ras protein is the thiol group found on cysteine or available on separation of the disulfide bridge of cystine or lipoic acid, cystine and to a lesser degree, lipoic acid, act as competitive inhibitor of isoprenylation of the thiol group on the Ras protein thereby disabling its

ability to stabilize in a membrane and blocking its carcinogenic activity. A typical dose would be 300 mg oral per day.

With respect to HIV and AIDS, and viral diseases, such as hepatitis C, the pharmacokinetics are similar to those described above. The diminution of energy in the cell by the action of the COX-2 inhibitor interferes with RNA synthesis, which synthesis has large energy demands and which synthesis is very sensitive to energy changes. Impaired energy levels impair accurate synthesis which is critical for viral disease to propagate and survive without being immediately recognized attacked by the body immune system. Cystine, which affects the glutathione pathway, independently strengthens immune system competency, and triggers more favorable Th1 response.

With respect to vascular associated disease, as defined, the anti-inflammatory effects of the COX-2 inhibitor are aided by the addition of cystine to the COX-2 inhibitor. The addition of cystine improves the likelihood of reducing vascular associated disease as the improvement in glutathione levels in macrophages decreases the formation of atherosclerotic plaque. Macrophage in the form of "foam" cells plays an important role in creating plaque at sites of damage and inflammation in the artery wall. The oxidation of low density lipoprotein (LDL) in the macrophage increases the inflammation, reaction and production of atherosclerotic plaque because macrophage-mediated oxidation of low-density lipoprotein (LDL) is thought to play a key role during early atherogenesis, and cellular oxygenases were shown to mediate this process (Free Radic Biol Med 1998 Jan 15:24(2): 305-17. The presence of glutathione at an adequate level has been demonstrated to be inversely related to the formation of oxidized LDL in the macrophage and the formation of atherosclerotic lesions. Id.

With respect to treatment for anti-viral diseases, HIV and immunocompromised individuals, cystine and the COX-2 inhibitor are best utilized in conjunction. The COX-2 inhibitor, in an analogous manner as for cancer cells, interferes with the energy cycle of the cell and thereby interferes with RNA synthesis in affected cells. Cystine directly enhances immune system competency and positively affects the glutathione pathway. HIV is notorious for interfering with glutathione pathway function, and triggering a lower Th1/Th2 ratio, thus triggering a less favorable inflammatory response. The combination of cystine and the COX-2 inhibitor diminishes the Th2 response, while simultaneously inhibiting its inflammatory effects.

The multiple stresses on the cancer cell's ATP cycle either disables or retards the cell's replication, subjects it to cell apoptosis, or renders it vulnerable to the body's defenses.

In sum, by interfering with the cyclooxygenase pathway, particularly important in the formation of prostaglandins, and thus in the cell-signaling mechanism critical for replication of cancer cells, by disorienting the feedback regulation system in the isoprenoid formation cycle, and later in that cycle, by utilizing a COX-2 inhibitor, preferably rofecoxib, to further inhibit the formation of cholesterol, the invention renders cancer cells vulnerable to poor replication and subject to bodily defenses, thus slowing the cancer activity, and in the instance of prostate cancer, lowering the PSA of the patient.

The invention also can utilize one or more of certain additional active agents in combination with the COX-2 inhibitor, or in combination with the COX-2 inhibitor, and cystine. The additional active agents can be in a single dosage formulation, or may be administered to the patient in a separate dosage formulation, which allows for concurrent or sequential administration. Examples of additional active agents which may be employed include squalene epoxidase inhibitors, squalene synthase inhibitors, probucal, glycoprotein IIb/IIIa fibrinogen receptor antagonists, and pharmaceutically acceptable salts of those additional active agents which do not interfere with the COX-2 inhibitor, and cystine. These and pharmaceutically equivalent agents in the same classes are described in the cited Winokur art, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease" and in Nichtberger, U.S. Pat. No. 6,136,804, Oct. 24, 2000. The therapeutically effective amount to use for these additional active agents is referred to in the just-cited art, can be seen in the Physician Desk Reference (PDR), and may be seen on the package inserts.

With respect to "A Composition and Method of Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent Preferably Using Selective COX-2 Inhibitor and HMG-CoA Reductase Inhibitor", and the use of this invention for a radiosensitizing agent and radioprotective agent, the cystine and the COX-2 inhibitor only, in conjunction with chemotherapy or radiotherapy, are proposed as an additional composition, to cause the osmolytic effect referenced in the provisional application entitled "A Composition and Method of

Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent Preferably Using Selective COX-2 Inhibitor and HMG-CoA Reductase Inhibitor.” The method of that provisional application is claimed using the cystine and the COX-2 inhibitor only in conjunction with the administration of chemotherapy or radiotherapy. While the combination of cystine, selective COX-2 inhibitor and HMG-CoA reductase inhibitor is believed more efficacious, the invention in “A Composition and Method of Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent Preferably Using Selective COX-2 Inhibitor and HMG-CoA Reductase Inhibitor” filed January 26, 2001, may be used without the HMG-CoA Reductase Inhibitor in conjunction with radiotherapy and chemotherapy.

The inventors also note the need for and claim a composition potentially including Selenium, and the method of administration potentially including Selenium, if a therapeutic window of Selenium in a patient is not present. See, Brooks and Nelson, Cancer Prevention and Control, Chemoprevention of Cancer at 369 (Marcel Dekker 1995). Selenium can be toxic, but there does need to be an adequate level of Selenium. The patient should be monitored and Selenium supplement given to achieve a therapeutic window for Selenium level to achieve the desired effect of allowing normal functioning of the glutathione pathway and maintaining integrity. In a normal healthy male, the adequate level is approximately 70 micrograms/70 kg of weight. The preferred mode would be a supplement in sequence with cystine administration, but a dose of any part of the invention could include Selenium. The method of treatment could include a sequential or simultaneous dose with either the cystine or the COX-2 inhibitor or both. However, toxic levels of selenium must be avoided. Thus, adequate level means only adequate level.

The inventors recognize that vitamin E deficiency may allow oxidative stress and the inventors claim that like Selenium, the level of Vitamin E must be maintained, but normal vitamin E levels per se do not strengthen the immune system sufficiently to deter metastasis.

Vitamin C also has antioxidative properties, and again the inventors recognize that vitamin C deficiency may allow oxidative stress and the inventors claim that like Selenium and Vitamin E, the level of Vitamin C must be maintained, but normal vitamin C levels per se do not strengthen the immune system sufficiently to deter metastasis. Vitamin C protects and maintains

the redox balance of the cell.

Adequate levels of Vitamin C and Vitamin E means, in this invention, for a cancer patient, approximately three times the recommended daily allowance as set out by the American Dietetic Association or the U.S. Dept. of Agriculture as published from time to time.

Discussion of certain specific patent and literature art:

One patent, Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease", and a corresponding U.S. Patent 6,245,797, claims a combination of a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events and a method of using a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events. Another patent, Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled "Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions" proposes the utilization for an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor to treat, prevent or reduce the risk of acute coronary ischemic syndrome, thrombosis, and related vascular problems.

Certain literature has suggested that COX-2 inhibitors may have efficacy toward certain cancers. A review article sets out a good summary of COX-2 inhibitors. Fosslien "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (2000). In unrelated research, COX-2 inhibitors were reported to be inhibiting certain cancers, particularly familial adenomatous polyposis. See, 319 (7218) British Medical Journal 1155 (Oct. 30, 1999). COX-2 inhibitors, in that instance, celecoxib, a COX-2 inhibitor manufactured by G.D.Searle, and sold under the brand name Celebrex, had caused a reduction in adenomatous polyps which are a virtual guarantor of cancer of the colon if left untreated. Cyclooxygenase-2 had been implicated in colorectal cancer and colonic tumorigenesis. See, "The Relationship Between Cyclooxygenase-2 Expressions and Colorectal Cancer", 282(13) J. Amer. Med. Ass'n:1254-1257 (Oct. 6, 1999).

Both celecoxib and rofecoxib are suggested to have similar effects. See, Vol. 56(2) Amer. J. of Health-System Pharmacy: 106-107 (Jan. 15, 1999). Unfortunately, like many (nonsteroidal anti-inflammatory drugs (NSAIDs), the COX-2 inhibitors are felt to cause a range of gastrointestinal problems.

Based on the pharmaceutical product description of Merck for simvastatin, which description is adopted herein and attached for reference, and which drug is marketed as ZOCOR, a registered trademark of Merck, simvastatin functions in a similar way to lovastatin, another drug marketed by Merck under the registered trademark of MEVACOR, the pharmaceutical product description for which is adopted herein and attached for reference. Both are derived from *aspergillus terreus*.

Certain literature has suggested that HMG-CoA inhibitors may have efficacy toward certain cancers. Based on an article entitled, "Caspase-7 is Activated During Lovastatin Induced Apoptosis of the Prostate Cancer Cell Line LNCaP" 58(1) Cancer Research: 76-83 (1998), and a second article "Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway Induces p53-independent Transcriptional Regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells", 273(17) J. Biol. Chem.:10628-23, (1998), lovastatin had therapeutic value in treating prostate cancer. Patients to whom were administered lipid lowering/modifying drugs such as lovastatin were suggested to be more cancer-free than those using bile acid-binding resins. See, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study, 160(5) Archives of Internal Med: 2363-2368 (2000). "Therapeutic Approaches to Bone Diseases [Bone Remodeling and Repair: Review]," Science, 289(5484), Sept. 1, 2000:1508-1514.

No patent or literature suggests that the substances be combined to treat cancer nor is the synergistic effect set forth in this specification suggested or described.

No patent or literature suggests the preferred embodiment that a COX-2 inhibitor be combined with an HMG-CoA inhibitor to retard cancer and be further combined with a glutathione-cycle enhancing compound such as cystine, cysteine, or N-acetyl-cysteine, also called NAC, to improve immune system competency to further retard cancer.

No literature suggests another preferred embodiment: using a COX-2 inhibitor and

HMG-CoA inhibitor set forth in this invention to retard cancer.

Reduction to practice:

The combination of a selective COX-2 inhibitor and an HMG-CoA reductase inhibitor exhibits the unexpected property of enabling management of cancer. This has been demonstrated in two specific instances. Both patients were diagnosed with Stage 4 metastatic cancer and were refractory to other treatments. The first patient had prostate cancer and showed a PSA (prostate specific antigen-a widely accepted marker of prostate cancer activity) of 71 according to the patient. The patient was placed on a regimen of VIOXX and MEVACOR, and has survived with good quality of life such as mowing his lawn, steady weight, and the like while the patient's PSA fell from tests conducted by one of the inventors to less than 2.5 with scan-documented lack of progression. A second patient diagnosed with pancreatic cancer which was also refractory to other treatment was placed on a regimen of VIOXX and MEVACOR with a whey supplement containing cystine and survived approximately four months and initially gained some weight since first presenting while sustaining a reasonable quality of life until death. Pancreatic cancer is one of the most intractable cancers known and any success with pancreatic cancer is surprising in light of existing literature and art.

Pharmacological compounds in this invention:

The science behind the combination is based on a triad of attacks in the biochemical cycles contributing to cancer cell replication.

Cancer cells must necessarily replicate for a "cancer" to thrive. Attacks on biochemical cycles at points where replication are involved are a favored approach. Cancer cells are particularly vulnerable to interference with lipid cell membrane status and ATP synthesis.

This invention proposes not only attack with a COX-2 inhibitor to interfere with the cyclooxygenase pathway, but by combination with an HMG-CoA reductase inhibitor, a statin, including simvastatin or lovastatin, focuses on another cycle, the formation of polyisoprenoids, particularly cholesterol.

The invention claims the use of selective COX-2 inhibitor, including rofecoxib or celecoxib, but the principles stated are generally applicable to all selective COX-2 inhibitors.

The meaning and definition of Cyclooxygenase-2 inhibitor ("COX-2 inhibitor" or

“selective COX-2 inhibitor”) in this invention shall include the following in this paragraph: all of the compounds and substances beginning on page 8 of Winokur WO99/20110 as members of three distinct structural classes of selective COX-2 inhibitor compounds, and the compounds and substances which are selective COX-2 inhibitors in Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled “Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions”, and the compounds and substances which are selective COX-2 inhibitors in Isakson et al, PCT application WO/09641645 published 27 December 1996, filed as PCT/US 9509905 on 12 June 1995, entitled “Combination of a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 Receptor Antagonist for the Treatment of Inflammations,” and in Waldstreicher, WO 01/45698, filed 18 December 2000, published June 28, 2001 entitled “Combination Therapy for Treating Neurodegenerative Disease.” Because the common names of some of the selective COX-2 inhibitor compounds are not given in Winokur, PCT WO99/20110, Nichtberger, U.S. Pat. 6,136,804, Isakson, PCT WO/09641645, and Waldstreicher, WO01/45698, the meaning of COX-2 inhibitor in this invention includes compounds that are selective COX-2 inhibitors, such as NS398 and DFU (see, YERGEY, JAMES A., et al., “In Vitro Metabolism of the COX-2 Inhibitor DFU, Including a Novel Glutathione Adduct Rearomatization,” Drug Metabolism and Disposition 29(5): 638-644 (The American Society for Pharmacology and Experimental Therapeutics 2001), also known as 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone. The meaning of COX-2 inhibitor in this invention includes compounds that are selective COX-2 inhibitors referenced in Fosslein, “Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia,” Crit. Rev. in Clin. Labor. Sci. 37(5):431-502 (CRC Press LLC 2000). The meaning of COX-2 inhibitor in this invention also includes rofecoxib, and celecoxib, marketed as VIOXX and CELEBREX by Merck and Searle/Pfizer respectively. Rofecoxib is discussed in Winokur, WO99/20110 as compound 3, on p.9. Celecoxib is discussed as SC-58635 in the same reference, and in T. Penning, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib), J. Med. Chem. 1997 Apr 25: 40(9): 1347-56. The meaning of COX-2 inhibitor in

this invention also includes SC299 referred to as a fluorescent diaryloxazole. C. Lanzo et al, "Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity", *Biochemistry* 2000 May 23 vol. 39(20):6228-34, and in J. Talley et al, "4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2)", *Med. Res. Rev.* 1999 May; 19(3): 199-208. The meaning of COX-2 inhibitor in this invention also includes valdecoxib, See, "4-[5-Methyl-3-phenylisoxazol-1-yl]benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2", *J. Med. Chem.* 2000, Vol. 43: 775-777, and parecoxib, sodium salt or parecoxib sodium, See, N-[[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanimide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration", *J. Med. Chem.* 2000, Vol. 43: 1661-1663. The meaning of COX-2 inhibitor in this invention also includes the substitution of the sulfonamide moiety as a suitable replacement for the methylsulfonyl moiety. See, J. Carter et al, Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors", *Bioorg. Med. Chem. Lett* 1999 Apr. 19:Vol. 9(8): 1171-74, and compounds referenced in the article "Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors", *Bioorg. Med. Chem. Lett* 1999 Apr. 19:Vol. 9(8): 1167-70. The meaning of this invention includes a COX-2 inhibitor, NS398 referenced in two articles: Attiga et al, "Inhibitors of Prostaglandin Synthesis Inhibit Human Prostate Tumor Cell Invasiveness and Reduce the Release of Matrix Metalloproteinases", *60 Cancer Research* 4629-4637, August 15, 2000, and in "The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2," Hsu et al, 275(15) *J. Biol. Chem.* 11397-11403 (2000). The meaning of COX-2 inhibitor in this invention includes the cyclo-oxygenase-2 selective compounds referenced in Mitchell et al, "Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy", *Brit. J. of Pharmacology* (1999) vol.128: 1121-1132, see especially p. 1126. The meaning of COX-2 inhibitor in this invention includes so-called NO-NSAIDs or nitric oxide-releasing-NSAIDs referred to in L. Jackson et al, "COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs: Do They Really Offer Any Advantages?", *Drugs*, June, 2000 vol. 59(6): 1207-1216 and the articles at footnotes 27, and 28.

Also included in the meaning of COX-2 inhibitor in this invention includes any substance that selectively inhibits the COX-2 isoenzyme over the COX-1 isoenzyme in a ratio of greater than 10 to 1 and preferably in ratio of at least 40 to 1 as referenced in Winokur WO 99/20110, and has one substituent having both atoms with free electrons under traditional valence-shell-electron-pair-repulsion theory located on a cyclic ring (as in the sulfylamine portion of celecoxib), and a second substituent located on a different ring sufficiently far from said first substituent to have no significant electron interaction with the first substituent. The second substituent should have an electronegativity within such substituent greater than 0.5, or the second substituent should be an atom located on the periphery of the compound selected from the group of a halogen F, Cl, Br or I, or A group VI element S or O. Thus for purposes of this last included meaning of a COX-2 inhibitor, one portion of the COX-2 inhibitor should be hydrophilic and the other portion lipophilic. Also included as a COX-2 inhibitor are compounds listed at page 553 in Pharmacotherapy, 4th ed: A Pathophysiologic Approach, Depiro et al (McGraw Hill 1999) including nabumetone and entodolac. Recognizing that there is overlap among the selective COX-2 inhibitors set out in this paragraph, the intent of the term COX-2 inhibitor is to comprehensively include all selective COX-2 inhibitors, selective in the sense of inhibiting COX-2 over COX-1. The package inserts for rofecoxib and celecoxib are attached and adopted herein by reference. The inventors add to the class of COX-2 inhibitors useful in the invention the drug bearing the name etoricoxib referenced in the Wall Street Journal, December 13, 2000 manufactured by Merck. See, also, Chauret et al, "In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)," Bioorg. Med. Chem. Lett. 11(8): 1059-62 (Apr 23, 2001). Another selective COX-2 inhibitor is DFU [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanone] referenced in Yergey et al, Drug Metab. Dispos. 29(5):638-44 (May 2001). The inventors also include as a selective COX-2 inhibitor flavanolignanes (sometimes also called flavonoids) which have selective COX-2 inhibitory activity over COX-1 inhibitory activity, including the flavanoid antioxidant silymarin itself, and an active ingredient in silymarin, silybinin, which demonstrated significant COX-2 inhibition relative to COX-1 inhibition. The silymarin also showed protection against depletion of glutathione peroxidase. Zhao et al,

“Significant Inhibition by the Flavonoid Antioxidant Silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion,” *Mol. Carcinog.* Dec. 1999, Vol 26(4):321-33 PMID 10569809. Silymarin has been used to treat liver diseases in Europe. Bombardelli et al, U.S. Pat. 5,912,265, June 15, 1999, and Bombardelli et al, U.S. Pat. 6,218,369, April 17, 2001 list compounds having similar characteristics and related to silymarin intended to be included as COX-2 inhibitors in this invention, including silymarin, silibinin, silidianin, silicristin, dehydrosilybin, and phospholipid complexes of one of those flavolignanes. The minimum recommended dose in the therapeutic window is 200-250 mg/day of those compounds.

The term COX-2 inhibitor includes all pharmaceutically acceptable salts for the selective COX-2 inhibiting compound selected. Examples of such salt forms of COX-2 inhibitors include but are not limited to salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamide, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glutamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methyglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, troethamine, and the like.

The HMG-CoA reductase inhibitor claimed in this invention is lovastatin or simvastatin or cholestin which are compounds related to *aspergillus terreus*. The principles of this invention are generally applicable to all statins. The meaning and definition of a 3-hydroxy-3-

methylglutaryl-Coenzyme-A reductase inhibitor ("HMG-CoA inhibitor") in this invention is any selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA into mevalonate, generally referred to as cholesterol-lowering statins, and includes

1) lovastatin, marketed under the trademark MEVACOR by Merck, and described, among other places in U.S. Pat. 4,231,938,

2) simvastatin, marketed under the trademark ZOCOR by Merck, and described, among other places in U.S. Pat. 4,444,784,

3) pravastatin, marketed under the trademark PRAVACOL by Bristol-Myers-Squibb, and described, among other places, in U.S. Pat. 4,346,227,

4) atorvastatin calcium, marketed under the name LIPITOR by Parke-Davis, and described, among other places, in U.S. Pat. 5,273,995,

5) cerivastatin sodium, marketed under the name BAYCOL, by Bayer, and described, among other places, in U.S. Pat. 5,177,080, and

6) fluvastatin sodium, marketed under the name LESCOL, by Novartis Pharmaceuticals, and described, among other places, in U.S. Pat. 5,354,772.

The term HMG-CoA inhibitor (used as shorthand for and also referred to as "HMG-CoA reductase inhibitor") further includes all HMG-CoA reductase inhibitors described in Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease," and the compounds and substances which are HMG-CoA inhibitors in Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled "Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions." The meaning of HMG-CoA inhibitor in this invention shall include the compounds and substances referenced and incorporated into Winokur WO99/20110 by reference to art therein, and the compounds and substances referenced and incorporated into Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, by reference to art therein. Compactin is also described as a fungi derived competitive inhibitor of HMG-CoA reductase. Lehninger, Principles of Biochemistry (3rd ed. 2000) at 811. An HMG-CoA reductase inhibitor, with the natural structure of lovastatin identical to the synthetic structure of lovastatin, can also be isolated from red rice yeast or the rice in sufficient quantity

and is an HMG-CoA reductase inhibitor. The red rice yeast is found as cholestin or cholestol and is available on the Internet from a variety of places including China Beijing Jingxin Biochemical Products Factor, Linxiao Rd. S., Daxing Count, Beijing, PRC or its U.S. agent PHC Resources, Inc., 77 Milltown Rd., East Brunswick, NJ 08816. The red rice yeast is referred to in an FDA warning letter of May 8, 2001 to Maypro Industries available at www.fda.gov/foi/warning_letters/g1249d.pdf.

Based on the pharmaceutical product description of Merck for simvastatin, which description is adopted herein and attached for reference, and which drug is marketed as ZOCOR, a registered trademark of Merck, simvastatin functions in a similar way to lovastatin, another drug marketed by Merck under the registered trademark of MEVACOR, the pharmaceutical product description for which is adopted herein and attached for reference. Both are derived from *aspergillus terreus*.

Recognizing that there is overlap among the HMG-CoA inhibitors set out in this paragraph and in the list of six HMG-CoA inhibitors set forth above, the intent of the term HMG-CoA inhibitor is to comprehensively include all HMG-CoA reductase inhibitors.

The term HMG-CoA inhibitor encompasses the pharmaceutically acceptable salts of an HMG-CoA inhibitor selected. The invention includes pharmaceutically active salts of an HMG-CoA inhibitor, which may include non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base. Examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, citrate, dihydrochloride, edentate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laureate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mutate, napsylate, mitrate, oleate, oxalate, pamaote, palpitrate, panthothenate, phosphate/diphosphate, polygalacturonate, potassium, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclolate, tosylate, triethiodide, and valerate. The principles are also applicable to the inclusion of an additional ingredient, namely an edible resin that binds bile acids and

prevents their reabsorption from the intestine, though this is not the preferred mode. Lehninger, Principles of Biochemistry (3rd ed. 2000) at 811.

Ester derivatives of the above described compounds included HMG-CoA inhibitors may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

The package inserts for COX-2 inhibitors and HMG-CoA inhibitors attached to the provisional application 60/245,592 and the description in the patents and methods in those patents related to the selective COX-2 inhibitors and HMG-CoA inhibitors are adopted by reference.

Cystine will be used as included in, and as a generic reference to glutathione pathway enhancing and detoxifying compounds in this description. Such compounds include the following in this invention:

Cystine is (3,3'-dithiobis [2-aminopropanoic acid]). Cystine is readily reduced to cysteine. Cystine is present in most mammalian hair and keratin.

Cysteine is 2-amino-3-mercapto propanoic acid. It is readily converted by oxiorreduction to cystine. It is a constituent of glutathione and abundantly present in the metallothioneines.

Cystine in the body-useful form as L-cystine is available from Spectrum Chemical Mfg. Corp. 14422 S. San Pedro St., Gardena, California 90248, and N-acetyl cysteine is also available there.

Cystine, cysteine, and N-Acetyl cysteine and pharmaceutically acceptable salts, including the pharmaceutically active forms described in Kozhemyakin et al, published by WIPO as WO 00/031120, PCT/RU99/00453, filed internationally on 19 Nov. 1999, "Hexapeptide with the Stabilized Disulfide Bond and Derivatives Thereof Regulating Metabolism, Proliferation, Differentiation and Apoptosis," will all collectively be referred to as cystine in this invention. Other glutathione pathway enhancing compounds understandable to one of ordinary skill in the art which are encompassed in the term NAC are stable forms of compounds that enhance the glutathione pathway, the substituents of which are suggested in Kozhemyakin et al, Hexapeptide with the Stabilized Disulfide Bond and Derivatives thereof Regulating Metabolism, Proliferation,

Differentiation and Apoptosis published as WO 00/31120, June 2, 2000. Included in the term NAC is also any therapeutically beneficial sulfur donating compound, including ebselen, which interacts with the glutathione pathway. The invention contemplates in the term NAC undenatured whey protein products designed to have enhanced cystine concentration as well as protein products which contain cysteine and cystine. They can be in the form of food products. Immunocal (a Registered Trademark of a product manufactured by Immunotec, Montreal Canada). Immunocal ® undenatured whey protein has the added advantage of providing the cysteine in the disulfide form, called cystine. 80% of the circulating cysteine in the body is in the form of cystine. Cystine is readily absorbed into cells and has been demonstrated to be preferred by certain cells such as astrocytes (Kranich O et al Glia, 22(1):11-8 1998).

NAC DOSING

IV infusion, 150mg/Kg in 250 ml of D5W over 15 minutes

followed by continuous infusion of 50 mg/kg in 500 ml over 4hr has been demonstrated to be safe and effective in a small study (Spanen H et al, "Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?," Chest, 113(6):1616-24 1998 Jun). The intravenous infusion could be continued to for as long as needed depending on the individuals response to the therapy .

Intravenous NAC is not normally recommended as a stand-alone therapy, but is envisioned to be used in combination with antibiotics when necessary. It would also be useful for use as an initial therapeutic for individuals who may have been exposed, and while confirmation of exposure is pending. In other words, a short IV dose will attenuate the impact of the anthrax toxin, reducing the likelihood of severe impact from the toxin and act as a preventative while confirmation of exposure is pending. The effect of NAC on the immune system would be beneficial even if the biological turned out to be something other than anthrax as the improved immune function would be useful in defending the individual against viruses (De Flora S, et al, "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment," Eur Respir J 1997 Jul;10(7):1535-41).

Intravenous NAC is manufactured using pharmaceutical grade NAC obtained from any major supplier of USP grade NAC, such as Spectrum Chemical of Gardena, California. The

amount of 0.8 grams of NAC are diluted in 100 ml sterile water or saline for injection. The process is performed using a layer of nitrogen gas to expel the excess oxygen overlying the liquid. This step is done to maintain an oxygen free environment that will limit the amount of oxidation that may occur during storage.

Oral dosage of NAC for prophylaxis is 500 mg. two or three times a day.

Intravenous glutathione is prepared in a similar fashion using reduced L-glutathione obtained from any major supplier of USP grade NAC, such as Spectrum Chemical, Gardena, California. The glutathione is diluted in sterile water or saline using 200 mg glutathione per ml of diluent.

Glutathione may be administered by inhalation with the use of a nebulizer. The reduced form of L-glutathione can be mixed in sterile saline in concentrations of 60mg/ml, 100 mg/ml and administered as 2 ml to 4 times per day. The frequency of administration will depend on the severity of the patients condition.

Inhaled glutathione 60 mg/ml may be mixed with NAC at a dose of 125mg/ml, and administered at a dose of 2ml 2 to 4 times a day.

The addition of cystine, cysteine, N-acetyl cysteine, or the pharmaceutically acceptable salt of those substances yields another effect in this invention not facially evident from the independent properties of the basic components of the invention (hereafter each substance or a pharmaceutically acceptable salt is referred to as a "cystine"). Administration of a cystine family member, preferably cystine, which has the best and most rapid upload into the glutathione pathway and better storage capability by the body, or N-acetyl cysteine, enhances the immune system competency of the patient.

In individuals on prophylactic antibiotic therapy for presumed exposure to anthrax the NAC can be continued for extended periods with oral ingestion of NAC or a cystine source such as undenatured whey protein such as Immunocal (a Registered Trademark of a product manufactured by Immunotec, Montreal Canada). Immunocal ® undenatured whey protein has the added advantage of providing the cysteine in the disulfide form, called cystine. 80% of the circulating cysteine in the body is in the form of cystine. Cystine is readily absorbed into cells

and has been demonstrated to be preferred by certain cells such as astrocytes (Kranich O et al Glia, 22(1):11-8 1998). Lipoic acid can be an adjunct to the cystine.

All of these cystine and cystine-like compounds function as a glutathione pathway enhancing and detoxifying compound. They have the additional benefit of ameliorating the negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA inhibitors, both as a combination and individually. The enhancement of the glutathione level and pathway has a second important and unexpected effect. The avoidance of a glutathione deficiency steers the patient to have a higher Th-1 response to Th-2 response ration that the patient would have with any glutathione deficiency. Peterson, J. et al, "Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns," Vol 95(6), Proceedings Nat'l Acad. Sci. USA p. 3071-76 (Mar. 17, 1998). This enhancement is independent of, but corollary to the combination of the COX-2 and HMG-CoA inhibitor.

Magnesium sulfate is available from Spectrum Chemical Mfg. Cor., 14422 San Pedro St., Gardena, California 90248 and should meet U.S. Pharmacopeia standards. Other Magnesium compounds are available from Spectrum Chemical or Sigma/ Aldrich of St. Louis Missouri.

DESCRIPTION OF INVENTION:

The preferred mode of invention without limiting its use or use of pharmaceutical equivalents to those described herein is to administer a therapeutic dose of a cyclooxygenase-2 inhibitor, namely VIOXX (a registered trademark of Merck Co. for a drug formally known as rofecoxib) or CELEBREX (a registered trademark of Searle and Pfizer for a drug formally known as celecoxib) (both referred to as a "COX-2 inhibitor"), in combination with a therapeutic dose of a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, namely with Mevacor (a registered trademark of Merck Co. for a drug formally known as lovastatin), or ZOCOR (a registered trademark of Merck Co. for a drug formally known as lovastatin) or cholestin (all referred to as "HMG-CoA inhibitor") starting with the minimum initial recommended doses of each drug on the package inserts in the Physician Desk Reference. This mode is therefore a COX-2 inhibitor beginning with an HMG-CoA inhibitor in the minimum doses for each. For patients who have advanced prostate cancer whose PSA does not respond to the combination, the

dosage should be increased in step wise fashion to the maximum dose in the therapeutic window. The preferred mode of so doing is to monitor the patient each six weeks. A person of ordinary skill in the medical arts can apply the regimen described in this specification.

An alternative is to administer a COX-2 inhibitor with cystine. The starting dose for the COX-2 inhibitor should begin with a minimum initial recommended dose in the Physician Desk Reference with a dose of cystine of approximately 350mg/70kg of L-cystine twice per day or the equivalent of other cystine compounds listed.

Additionally, selenium should be administered orally after treatment in the amount of 200µg to maintain adequate levels. Selenium is an important catalyst for glutathione peroxidase activity in the glutathione cycle enabling the capture and excretion of free radicals, especially hydroxyl radicals.

Administration of Vitamin C (1-5g) and oral Vitamin E (800-1200IU) to maintain normal levels is also appropriate and to prevent any deficiency in those vitamins from interfering with the efficacy of the treatment protocol.

The inventors suggest measuring at least cholesterol level and isoprostane level. If a patient's cholesterol level is decreasing, then the HMG CoA inhibitor is affecting cholesterol synthesis. If isoprostane levels are rising, then the COX-2 inhibitor should be having an effect. The lack of change in one or the other suggests that the medication to achieve the desired metabolic pathway effect should be adjusted.

Another way to test for effectiveness and enable dosage adjustment is to test cytokine levels. Once at least two inflammatory response markers show therapeutic change then the combination should be having an effect. The preferred markers include upregulation of IL-12 and downregulation of IL-10. "Specific inhibition of cyclooxygenase restores anti-tumor reactivity by altering balance of IL-10 and IL-12 synthesis", J. Immunol 2000 vol 164(1) :361-370 [increased COX-2 expression increases PGE-2 which induces IL-10; accordingly, use of COX-2 inhibitor leads to down-regulation of IL-10; also observed concomitant upregulation of IL-12]. Testing of cytokines involves the use of ELISA assays to determine cytokine levels. Chemoluminescence tests are also used for certain interleukins. Other useful inflammatory response markers that may be tested include:

Test/	FactorName/range	Brief description
CRP	C-reactive protein	General inflammatory response marker, downregulation indicates amelioration of inflammatory response mechanism
IL-10	Interleukin-10 ED ₅₀ =0.5 ng-1ng/mL	Potent blocker of activation of cytokine synthesis and several accessory functions of macrophages; produced in CD4+ T cells and T cell clones, and other cells; downregulation indicates lessened interference with cytokine synthesis of cytokines needing upregulation and lessened macrophage activity interference
IL-2	Interleukin-2 0.0-4.0 pg/mL	Activates lymphocytes, potent stimulator of cytokine activated killer cells (LAK's) which demonstrate enhanced MHC non-restricted cytotoxicity. Used for renal cell CA-encourage Tcd activity
IL-6	Interleukin-6 0.0-149 pg/mL	Involved in T-cell activation; in nesting cells induce the expression of receptors for T-cell growth factor. Very important in inducing B-cells to differentiate into antibody-forming cells. In liver, it stimulates production of acute phase proteins. Growth factor for multiple myeloma
IL-8	Interleukin-8 0.0-70 pg/mL	Proinflammatory cytokine released from range of cells including monocytes, endothelial cells, epithelial cells, hepatocytes, fibroblasts and chondrocytes
IL-12	Interleukin-12	Potent initial stimulus for T-and Nk-cell, IFN(IFN=interferon)-

	Range 0.7pg/mL-7000pg/mL	<p>γ production. May encourage Tc1 generation. Potentiates NK cell</p> <p>to release IFN-γ. Works in a manner complementary to IL-10; increase in level compared to baseline indicates potential for increased cell-mediated response</p>
TNF	Tumor Necrosis Factor 0.0-4.9 pg/mL	Activates macrophage (m ϕ s) and neutrophils
IFN- γ	Interferon-gamma 0.0-1.5pg/mL	Encourages Tc1 generation role in early phase of immune response including antiviral and antiproliferative properties
IFN- α	Interferon-alpha 0.0-1.5 pg/mL	Induces IL-2 and can be used to switch Th cells from a Th2 to a Th1 profile
ECP	Eosinophilic cationic protein 1.5-5.5mg/mL	Potent indicator of eosinophilic degranulation resulting in a wide range of inflammatory conditions: autoimmune disease, bronchial asthma, parasitic infections, viral infections
IL-10	Interleukin-10 ED ₅₀ =0.5 ng-1ng/mL	Potent blocker of activation of cytokine synthesis and several accessory functions of macrophages; produced in CD4+ T cells and T cell clones, and other cells; downregulation indicates lessened interference with cytokine synthesis of cytokines needing upregulation and lessened macrophage activity interference

Advanced prostate cancer particularly refers to prostate cancer that has not been successfully treated by surgery, chemotherapy, radiation and/or androgen suppressant(s).

The same regimen is proposed for the commencement of treatment of other cancers.

The preferred mode of invention without limiting its use or use of pharmaceutical equivalents to those described herein is to use VIOXX (a registered trademark of Merck Co. for a

drug formally known as rofecoxib) or CELEBREX (a registered trademark of Searle and Pfizer for a drug formally known as celecoxib) (both referred to as a "COX-2 inhibitor"), in combination with a therapeutic dose of a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, namely with Mevacor (a registered trademark of Merck Co. for a drug formally known as lovastatin), or ZOCOR (a registered trademark of Merck Co. for a drug formally known as lovastatin) or cholestin (all referred to as "HMG-CoA inhibitor") starting with the minimum recommended starting doses of each drug on the FDA package inserts attached to provisional application 60/245,592 for the treatment of prostate cancer, or the minimum therapeutically effective amount.

The invention retards or drives prostate cancer into remission, best illustrated by lowering the Prostate Specific Antigen, the standard measure of prostate cancer activity in the human body.

The method of the invention is the step of administering the combination of COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin or simvastatin and rofecoxib or celecoxib, or the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin and rofecoxib. An alternative of this method of the invention is the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin or simvastatin and rofecoxib or celecoxib. Celecoxib may be used in lieu of rofecoxib, and simvastatin in lieu of lovastatin.

Another preferred method is the step of administering the combination of COX-2 inhibitor, HMG-CoA inhibitor, particularly lovastatin or simvastatin and rofecoxib or celecoxib, along with cystine as a glutathione pathway enhancing and detoxifying compound. An alternative of this method of the invention is the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, particularly including lovastatin or simvastatin, and rofecoxib or celecoxib, along with cystine as a glutathione pathway enhancing and detoxifying compound.

Also part of the invention is the method of manufacturing a combination of a COX-2 inhibitor and magnesium compound, that is manufacturing a combination of a COX-2 inhibitor, including rofecoxib or celecoxib, and magnesium sulfate. . Also part of the invention is the method of manufacturing a combination of a COX-2 inhibitor, especially rofecoxib or celecoxib,

along with cystine as a glutathione pathway enhancing and detoxifying compound. Added to that could be a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor such as lovastatin or simvastatin.

Thus, the prior discussion reviews one preferred mode of the invention, a COX-2 inhibitor and cystine. Another mode of the invention includes a COX-2 inhibitor with cystine, and an HMG-CoA inhibitor, including rofecoxib or celecoxib and lovastatin or simvastatin and cystine or another glutathione pathway enhancing compound. Especially for migraine type neurological afflictions, the addition of magnesium sulfate is preferred. As ATP and cholesterol synthesis is being affected in the cancer cell, cystine is being used to enhance the immune system competency and assist normal cells, through the glutathione pathway, in maintaining their stability.

The invention also can utilize one or more of certain additional active agents in combination with the HMG-CoA inhibitor and COX-2 inhibitor, or in combination with the HMG-CoA inhibitor, COX-2 inhibitor, and cystine. The additional active agents can be in a single dosage formulation, or may be administered to the patient in a separate dosage formulation, which allows for concurrent or sequential administration. Examples of additional active agents which may be employed include squalene epoxidase inhibitors, squalene synthase inhibitors, probucal, glycoprotein IIb/IIIa fibrinogen receptor antagonists, and pharmaceutically acceptable salts of those additional active agents which do not interfere with the HMG-CoA inhibitor and COX-2 inhibitor combination and method or with the HMG-CoA inhibitor, COX-2 inhibitor, and cystine. These and pharmaceutically equivalent agents in the same classes are described in the cited Winokur art, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease" and in Nichtberger, U.S. Pat. No. 6, 136,804, Oct. 24, 2000. The therapeutically effective amount to use for these additional active agents is referred to in the just-cited art, can be seen in the Physician Desk Reference (PDR) 2001, and may be seen on the package inserts.

The instant pharmaceutical combination comprising an HMG-CoA inhibitor in combination with a COX-2 inhibitor and cystine includes administration of a single pharmaceutical dosage formulation which contains both the HMG-CoA inhibitor and the COX-2

inhibitor and cystine, as well as administration of each active agent in its own separate pharmaceutical dosage formulation. A cystine supplement taken at a different time of day may be a separate dose without the HMG-CoA inhibitor or the COX-2 inhibitor. Cystine is the suggested glutathione pathway enhancing and detoxifying compound. The amount of cystine to be included in an oral dosage combination is a therapeutically effective amount to reach normal glutathione levels. Such therapeutically effective amount should preferably and initially be 140mg/70 Kg man twice per day.

Where separate dosage formulations are used, the substances claimed can be administered at essentially the same time, i.e., concurrently, or at staggered intervals, i.e., sequentially. The instant pharmaceutical combinations are understood to include a single pharmaceutical dosage formulation, as well as administration of each active agent in its own separate pharmaceutical dosage formulation. Administration in these various ways is suitable for the present invention as long as the beneficial pharmaceutical effect of the active agents are realized by the patient at substantially the same time. Such beneficial effect is preferably achieved when the target blood level concentrations of each active drug are maintained at substantially the same time. In all courses of administration, the therapeutic doses for cystine can be added, and likely necessitate an additional therapeutic dose early in the administration regimen. As much as possible, a single oral dosage formulation is preferred. A single dosage formulation will provide convenience for the patient, which is an important consideration especially for patients who may be in need of multiple medications. Administration of the COX-2 inhibitor or cystine, or if added, the HMG-CoA inhibitor, can be by tablet, liquid suspension, or many other pharmaceutically acceptable carriers known by or used by reasonably skilled practitioners in the art of pharmacology or pharmacological manufacturing including by the combinations and methods in the cited Winokur art, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease," Nichtberger, U.S. Pat. No. 6,136,804, Oct. 24, 2000, Waldstreicher, WO 01/45698, filed 18 December 2000, published June 28, 2001 entitled "Combination Therapy for Treating Neurodegenerative Disease." These pharmaceutically acceptable carriers can be adjusted by a person of ordinary skill in the art of pharmaceutical delivery.

The active drugs can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. The active drugs may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. They may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the active drugs may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. All of these are described in Nichtberger, U.S. Pat. 6,136,804, Oct. 24, 2000.

The term "therapeutically effective amount" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. A therapeutic change is a change in a measured biochemical characteristic in a direction expected to alleviate the disease or condition being addressed. The term "prophylactically effective amount" is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. In the preferred mode, the prophylactically effective amount is intended to begin with the minimum recommended dose. The term "therapeutic window" is intended to mean the range of dose between the minimal amount to achieve any therapeutic change, and the maximum amount which results in a response that is the response immediately before toxicity to the patient. The term "minimum recommended dose" is that amount either recommended in the package insert for the selected FDA approved drug, or for other substances and compounds, the minimum therapeutically effective amount for a typical patient of the size and weight being treated, meaning

that amount sufficient to precipitate a therapeutic change in condition of a patient for the use of the drug or substance alone for conditions it is designed to treat alone. Minimum recommended dose in the context of commencing treatment is also referred as the minimum initial recommended dose and is that amount recommended for patients as the starting dose. Adjustment of dose upward by 10% or "dose being adjusted upward by at least 10% of the previous dose" means increasing the dose by that approximate amount. In some instances the pharmaceutical carrier, or pill may have to be divided, but generally an increase to the next highest dose is acceptable within the therapeutic window. The references in the claims to specific dosages of specific FDA approved drugs are to tablets having those dosages as referenced in the package inserts adopted herein by reference from Prov. Appl. 60/249,592 dated November 17, 2000. The suggested starting dose for cystine is described in this invention as is the suggested starting dose for silymarin and related compounds to silymarin.

The dosage regimen utilizing an HMG-CoA inhibitor in combination with COX-2 inhibitor is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the cardiac, renal and hepatic function of the patient; and the particular compound or salt or ester thereof employed. Dosages in all events should be limited to the therapeutic window. Since two different active agents are being used together in a combination therapy, the potency of each of the agents and the interactive effects achieved by combining them together must also be taken into account. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective amount.

Discussion of pharmacokinetics and summary of literature:

The literature has suggested that an HMG-CoA reductase inhibitor may separately have efficacy toward cancers, and that a selective COX-2 inhibitor may separately have efficacy toward certain cancers, but no literature suggests that the substances be combined to treat cancer.

In drawing conclusions concerning the pharmacokinetics, the inventors observe that an intriguing and surprising aspect of the invention, which suggests many of the pharmacokinetics, is that quality of life is not substantially affected by the treatment; the patient is alive, the patient

does not die; at the same time, at least in the short term, the cancer is also present albeit repressed in its activity. The consideration of pharmacokinetics attempts to comprehend these combined phenomena.

An important aspect of the pharmacokinetics is the selectivity to cancer cells and essentially microadministration of cancer therapy. For instance, this invention proposes to affect ubiquinones in important ways. There is art emerging, subsequent to provisional application 60/263,486, to a pending trial of Ubiquinone under a trade name of Ubigel by Gel-Tec, Drug Facts and Comparisons, 55th ed. 2001 at KU-16 (Publ. by Facts & Comparisons 2000). Ubiquinone or CoQ-10 administration, in itself, is not likely have the benefits of the present invention because it is proposed to be administered by macroadministration to the entire organism, either orally or intravenously or in the general vicinity of the tumor area.

By contrast to such effort at macroadministration, this invention proposes virtual selective-to-cancer microadministration utilizing the body's own metabolic mechanisms and responses. This is a unique aspect of this invention and an important concept behind the invention. The inventors propose that one of the dilemmas of cancer therapy is to deliver the needed dose to the right place and minimize harm when the therapy is not in the right place.

The inventors believe that the most optimal treatments involve the utilization of the biochemical physiologic machine of the body, and preferably of the individual cell, to construct, manufacture and adjust the individual cell chemistry to achieve the desired object: in the case of the cancer cell or other afflicted and undesired cell, to disrupt its mechanisms of replication, primarily by focusing on the energy mechanism of the cell with the corollary result of interfering with membrane synthesis and cell replication, and in many instances, as the cell struggles to reach homeostasis, inducing apoptosis.

In sum, by interfering with the cyclooxygenase pathway, particularly important in the formation of prostaglandins, and thus in the cell-signaling mechanism critical for replication of cancer cells, by directly interfering, using an HMG-CoA inhibitor, namely lovastatin, with polyisoprenoid formation and disorienting the feedback regulation system in that formation cycle, and later in that cycle, by utilizing a COX-2 inhibitor, preferably rofecoxib, to further inhibit the formation of cholesterol, the invention renders cancer cells vulnerable to poor replication and

subject to bodily defenses, thus slowing the cancer activity, and in the instance of prostate cancer, lowering the PSA of the patient while destroying cancer cells.

The COX-2 inhibitor and the cyclooxygenase-prostaglandin pathway

The COX-2 inhibitor interferes with the operation of the cyclooxygenase cycle from which are generated prostaglandins critical in cell division chemistry. Direct inhibition occurs of the synthesis of COX-2, a precursor of prostaglandins. Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, published by Ciba-Geigy (1986) ISBN -0-91-4168-53-3, Lib. Cong. Cat. No. 81-70045 pp. 25-27 attached to Prov. Appl. 60/245,592, the text of which attachment is adopted by reference herein). This effect has been discussed in the literature. Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (November 2000). As also previously referenced, COX-2 inhibitors were reported to be inhibiting certain cancers, particularly familial adenomatous polyposis. See, 319 (7218) British Medical Journal 1155 (Oct. 30, 1999). COX-2 inhibitors, in that instance, celecoxib, a COX-2 inhibitor manufactured by G.D.Searle, and sold under the brand name Celebrex, had caused a reduction in adenomatous polyps which are a virtual guarantor of cancer of the colon if left untreated. Cyclooxygenase-2 had been implicated in colorectal cancer and colonic tumorigenesis. See, "The Relationship Between Cyclooxygenase-2 Expressions and Colorectal Cancer", 282(13) J. Amer. Med. Ass'n:1254-1257 (Oct. 6, 1999).

Both celecoxib and rofecoxib are suggested to have similar effects. See Vol. 56(2) Amer. J. of Health-System Pharmacy: 106-107 (Jan. 15, 1999).

One of the clear benefits of the selective COX-2 inhibitor is that COX-1 isoenzymes have what has been characterized as having general housekeeping functions generally ameliorative to bodily health. . Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (November 2000). Aspirin, a classic COX inhibitor, also inhibits COX-1, thereby achieving anti-inflammatory effect, for which aspirin is well-known, at the cost of beneficial aspects of COX-1 isoenzymes. Thus, a COX-2 inhibitor that is selective is important in the invention.

A selective COX-2 inhibitor is important to this cancer management invention, but as the literature indicates, does not provide a comprehensive answer nor a comprehensive cancer response.

The COX-2 inhibitor and angiogenesis

In mice, a COX-2 inhibitor, NS398, was reported to inhibit angiogenesis of a prostate cancer specimen in vivo. Liu et al, "Inhibition of Cyclooxygenase-2 suppresses Angiogenesis and the Growth of Prostate Cancer in Vivo," 164 J. of Urology 820-825 (September 2000) at 820.

Inhibition of cholesterol synthesis by COX-2 inhibitor and HMG-CoA inhibitor:

In viewing the biochemical cycle through which the formation of polyisoprenoids occurs, there are a series of intermediates. See, Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, published by Ciba-Geigy (1986) ISBN -0-91-4168-53-3, Lib. Cong. Cat. No. 81-70045 pp. 25-27, 142-147 (attached to Prov. Appl. 60/245,592, the text of which attachment is adopted by reference herein). A key end product of the biochemical cycle of formation of polyisoprenoids is cholesterol. In order for a cell to replicate successfully, the entire cholesterol cycle must be functioning properly and cholesterol is especially critical to membrane stabilization, a necessary ingredient for successful cancer cell replication.

The "early" cholesterol pathway: Acetyl CoA to mevalonate

Examining the intermediates in the polyisoprenoid formation cycle carefully, beginning with Acetyl-CoA, the next intermediate is 3-Hydroxy-3-methylglutaryl-CoA ("HMG-CoA"). There is a feed back regulation mechanism immediately after this intermediate before transition occurs to the next intermediate: Mevalonate. Salway, Metabolism at a Glance, 88-89 (Blackwell Science 2nd ed. Oxford 1999). The invention proposes to use lovastatin as an HMG-CoA reductase inhibitor. An HMG-CoA reductase inhibitor interferes in the polyisoprenoid formation cycle, and particularly interferes with cell wall synthesis, thereby interfering with a necessary construct of cancer replication. Because ATP cycle intermediaries are juxtaposed to the HMG-CoA feedback mechanism, and ATP and ATP cycle intermediaries are apparent in transition steps of biosynthesis of cholesterol subsequent to the Mevalonate intermediate, the effect of a cancer cell starved of necessary cholesterol is to biochemically invite increased production of intermediaries in the transition from mevalonate to cholesterol, and to biochemically invite

increased production of HMG-CoA, whose biosynthesis is being inhibited. Such increased production draws on the ATP and ATP cycle intermediaries in the cancer cell.

The later cycle: squalene to cholesterol synthesis

Continuing examination of the polyisoprenoid formation cycle, after the Mevalonate intermediate, the cycle continues with the formation of isopentenyl diphosphate, and then farnesyl diphosphate. Three intermediate products emerge after the farnesyl diphosphate intermediary: squalene, dolichols and ubiquinone. Salway, Metabolism at a Glance at 88-89, (Blackwell Science 2nd ed Oxford 1999).

A second effect cooperates with the HMG-CoA inhibitor to exacerbate the energy drain on a cancer cell. This collateral effect is additional to the effect of a COX-2 inhibitor on the cyclooxygenase cycle. While the HMG-CoA inhibitor has decreased the production of the subsequent intermediates to farnesyl pyrophosphate, the COX-2 inhibitor, because of the active electron field substituents, also interferes in a way not discussed in the literature with the normal biochemistry of squalene to cholesterol synthesis. Squalene transitions through a complex series of intermediates to cholesterol. This interference in the biosynthesis pathway subsequent to squalene synthesis further disables the cell division chemistry of a cancer cell and leaves it vulnerable to apoptosis. Notably, the transition states from squalene to cholesterol between intermediaries depend on critical inputs of ATP cycle chemicals, including NADP and NADPH. Salway, Metabolism at a Glance at 88-89, Blackwell Science 2d ed 1999). A COX-2 inhibitor interferes with, but does not appear to stop, synthesis of certain of these intermediaries. This either results in insufficient cholesterol for cancer cell replication or results in introduction of further drain on the ATP cycle chemicals to produce the desired cholesterol critical for cell replication. This drain on the ATP cycle is beyond the stresses already imposed by the HMG-CoA inhibitor. As the replicating cell has further need for cholesterol, further energy is diverted from the cell.

The "middle" of the cholesterol synthesis cycle: Farnesyl Pyrophosphate and ubiquinones

A corollary effect of the partial inhibition of the production of cholesterol from squalene and the triggering of increased production of farnesyl pyrophosphate is that relatively more ubiquinones are produced which are not being inhibited in the same manner as the squalene

to cholesterol synthesis is inhibited.

Ubiquinones are key participants in the Q cycle in mitochondrial respiration. With the relative overproduction of ubiquinone that occurs in order to attempt to produce the requisite cholesterol for cell replication, one of two effects, or both effects, occur on mitochondrial respiration.

The replicating cancer cell either comes under osmotic pressure to decrease the concentration of ubiquinone, or the increased ubiquinone concentration changes the electron transport mechanism in the inner membrane of the mitochondria. If the cell admits fluid to stabilize the ubiquinone concentration, the cell must normally change size or shape to do so. Ellerby et al, Measurement of Cellular Oxidation, Reactive Oxygen Species, and Antioxidant Enzymes during Apoptosis, 322 Method in Enzym. 413 (Academic Press 2000), Bortner, Volume Regulation and Ion Transport during Apoptosis, 322 Method in Enzym. 421 (Academic Press 2000).

If the increased ubiquinone concentration changes the electron transport mechanism, the predicted effect is that there is a change in electron transfer from Complex 1 toward Complex 3. See Metabolism at a Glance, J.G. Salway, p. 12-15 (Blackwell Science Ltd., Oxford and London, 2nd ed. 1999).

Simultaneous to the ubiquinone effect, giving attention to both the COX-2 inhibitor with the hydrophilic and lipophilic substituents referred to earlier in this specification and the chemical potential of the unpaired electrons on the first and second substituents, the electrochemical potential and gradient between the matrix side of the membrane and the opposite side membrane is changed, which affects the proton pump and migration of H⁺ ions and in turn interferes with ATP synthesis. The likely reason is one of several, or a combination of several reasons. The COX-2 inhibitor, by changing the electrochemical gradient and potential across the membrane inhibits the potential need for ATP synthesis. Further, the electron attraction to the H⁺ cations on the matrix side, likely from the O=S=O bond in rofecoxib (or celecoxib), either slows the cation, potentially bonds and neutralizes them, or if an excess of electrons pushed by the ubiquinone shuttle from complex II to complex III encounters the cations, they potentially neutralize the H⁺ cations.

The cancer cell has an opportunity to again change the concentration to proper levels, but another osmotic pressure is generated. Any disruption in ion transport that produces excess cytochrome would either be potentially fatal to the cell, or require yet another osmotic effect. Bortner suggests a volume loss or movement of ions is associated with cell apoptosis. "Cell volume is normally controlled within narrow limits." Bortner, 322 Methods in Enzym. 422. Ellerby associates any change in cell size as either a coincident event to apoptosis or a precursor to completion of apoptosis phases. Ellerby, 322 Methods in Enzym. at 413-415. Bortner proposes the thesis that "When cells are placed in a hypertonic environment, shrinkage occurs because of the loss of osmotically obligated water. However, over a period of time diverse cell types compensate for the volume loss by activating a regulatory volume increase (RVI) response. This response allows for an influx of ions, with the concomitant movement of water into the cells to achieve a near-normal size." Bortner, 322 Methods in Enzym. 422. Thus, there is movement of osmotically obligated water from the cell [or to the cell] to achieve a near normal cell size. If not successful, excess cytochrome has been implicated in the generation of caspases which often lead to cell apoptosis. Ellerby, 322 Methods in Enzym. 413-415.

Thus, the novel combination for retarding cancer does so in part by producing osmotic stress selectively in cancer cells, and in part by interfering with membrane synthesis in cancer cells. Movement of any osmotically obligated fluid has a corollary effect of also speeding into replicating cells potentially detrimental biochemicals from the body's own immune system. Another corollary of any change in electrochemistry in the area of the matrix or the size of the cell is damage to ion transport channels, the blockage or overexpansion of which ion transport channel is often fatal to the cell. Ellerby, 322 Methods in Enzym. 413-421, Bortner, 322 Methods in Enzym. 421-433. The result of mitochondrial respiration uncoupling has been observed in conjunction with non-steroidal anti-inflammatory drugs. Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502, pp. 453-455 (November 2000).

Since cancer replication is very sensitive to ATP cycle disruptions, the effect is to divert cell energy "unnecessarily" to attempting to overcome the effect of the HMG-CoA inhibitor and the COX-2 inhibitor and starve the cancer cell of necessary energy resulting in cytotoxic effect,

apoptotic effect, or inhibition of replication.

Selectivity to cancer cells as a result of anaerobic function of cancer cells

The invention, either in the preferred mode of lovastatin and rofecoxib, or the alternative preferred mode of lovastatin, rofecoxib and cystine, takes advantage of the increased ratio of anaerobic to aerobic functionality of a cancer cell compared to that ratio in a normal cell. In the process of replication and mitosis, the growth rates of cancers parallel their level of differentiation and the relative number of their cells in mitosis. Mitoses are more abundant in the anaplastic rapidly dividing variants, meaning in the cancer cells that are creating "clones" of each other by cell division and replication. In most cancers that are associated with an increased number of mitoses and growth rate of cells, such proliferative activity results from the apparent loss of regulatory mechanisms apparent in normal cells. Cancer cells, without these regulatory mechanisms, are so engaged in the mitosis process with its significant energy demands, that both aerobic energy generation and anaerobic energy generation mechanisms are utilized. Nelson and Cox, Lehninger, Principles of Biochemistry (3rd ed. 2000) at 541.

In a normal cell, the combination of glutathione and internal cell biochemical controls enable an efficient disposition of cell wastes. In a cancer cell, the anaerobic processes of the cell to meet the cell's energy demands result in use of glycolytic mechanisms even in the presence of what would be adequate oxygen supplies in a normal cell. The increased glycolytic processes, particularly the anaerobic processes, generate relative more waste product such as CO₂ and lactic acid. Metabolism at a Glance, J.G. Salway, p. 32-33, 68-69 (Blackwell Science Ltd., Oxford and London, 2nd ed. 1999). Moreover, the COX-2 inhibitor shifts the reaction equilibrium to promote a higher concentration of arachidonic acid. Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, publ. by Ciba-Geigy (1986), p. 25-27; . Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431, 433 (November 2000). Such relatively acidic environment in the cancer cell interferes with the functionality of the glutathione pathway which pathway is less efficient in an acidic environment.

Classic biochemistry indicates that the concentration of glutathione will fall in a more acidic environment such as the relatively more acidic cancer cell. Glutathione is gamma-Glu-Cys-

Gly. The COO⁻ ion on the end of the chain will be more present and a more favored species in the less acidic environment of the normal cell.

The glutathione functionality is important in reducing reactive oxygen species to relieve subsequent oxidative stress which is deleterious to any cell. The effect in the cancer cell of the relatively reduced glutathione functionality and generation of increased wastes from increased and unregulated glycolysis is to either cause a slowing of the processes leading to waste production, thereby slowing replication, or to cause a change in osmolarity of the cell which is normally offset by increased water and a corresponding change in cell size. By contrast, in normal cells, an enhancement in relief of oxidative stress occurs, as well as maintenance of full functionality, thereby strengthening the immune system competency and total body system.

Another accomplishment of the invention not suggested by the literature is to utilize cystine to ameliorate the negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA inhibitors, both as a combination and individually. Unfortunately, like many non-steroidal anti-inflammatory (NSAIDs), the COX-2 inhibitors are felt to cause a range of gastrointestinal problems. This amelioration by the invention of negative renal, gastric and hepatic effects is accomplished by cystine, especially in a glutathione deficient patient.

The avoidance of a glutathione deficiency steers the patient to have a higher Th-1 response to Th-2 response ratio than the patient would have with any glutathione deficiency. Peterson, J. et al, "Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns," Vol 95(6), Proceedings Nat'l Acad. Sci. USA p. 3071-76 (Mar. 17, 1998). This ameliorates negative gastrointestinal hepatic and renal effects. Another article, discussing 5-HETE and its association with prostate cancer, suggests that N-acetyl cysteine in the invention would not be efficacious. Miller et al, , "5-HETE Congeners as Modulators of Cell Proliferation," Bioorg. Med. Chem. Ltr. 10(17): 913-916 (Sep. 4, 2000).

The second and unexpected enhancement is independent of, but corollary to, the combination of the COX-2 inhibitor and HMG-CoA inhibitor. Though no source is cited, Fosslien suggests that antioxidants such as TROLOX also inhibit COX-2 induction: "Inhibitors of COX-2 induction are tumor suppressor protein p53, estrogen, and antioxidants such as Trolox (N-acetylcysteine, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), PDTC, and

U75006" Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431, 433 (November 2000). TROLOX is not practical for combating cancer in mammals because it is an extremely powerful anti-oxidant and potentially toxic. In this invention, a more specific anti-oxidant that affects the glutathione pathway and which will have additional COX-2 inhibition characteristics is used. See Fosslien, Crit. Rev. in Clin. Lab. Sci. 37(5): 431 (Nov. 2000).

The correlative effect is that the invention takes advantage of the very "strengths" of the vigorously metastasizing cancer whose strengths weaken the cancer cell's response to cystine and the glutathione pathway because of the cancer cell's Gompertzian growth characteristic.

Lovastatin, its interaction with a selective COX-2 inhibitor and isoprostanes and the lipoxigenase pathway.

The cited article entitled, "Caspase-7 is Activated During Lovastatin Induced Apoptosis of the Prostate Cancer Cell Line LNCaP" 58(1) Cancer Research: 76-83 (1998), and a second article, Lee et al, "Inhibition of the 3-hydroxy-3methylglutaryl-coenzyme A reductase pathway Induces p53-independent Transcriptional Regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells", 273(17) J. Biol. Chem.:10628-23, (1998), reported that lovastatin had therapeutic value in treating prostate cancer. Patients to whom were administered lipid lowering/modifying drugs such as lovastatin were suggested to be more cancer-free than those using bile acid-binding resins. See, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study, 160(5) Archives of Internal Med: 2363-2368 (2000).

Lovastatin can be predicted to have another cooperative effect with rofecoxib with respect to cancer, especially prostate cancer. There is strong evidence that oxidative stress and subsequent free radical damage is very important in prostate cancer. Chung et al, Prostate Cancer: Biology, Genetics and the New Therapeutics, "Chemoprevention of Prostate Cancer" by Brooks and Nelson p. 365-375 at p. 369(Humana Press 2001).

COX-2 inhibitor and the lipooxygenase pathway

In examining the cyclooxygenase pathway, see Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, publ by Ciba-Geigy (1986), p. 25, by application of Le Chatelier's principle, an inhibition of the cyclooxygenase pathway will cause the concentration of arachidonic acid to increase. Such increased concentration will cause an increase in products produced in the lipooxygenase pathway. One of those products is Leukotriene B4. Leukotriene B4 is implicated in lipoperoxidative stress to cells.

The lipooxygenase pathway and isoprostanes

As a cancer cell signals for increased COX-2 expression which is being inhibited, the signal is directed to creation of further arachidonic acid ("AA"). The differentiation from normal cells is that a normal cell is not signaling for more AA to delivery more COX-2 expression.

From both COX-2 inhibition and saturation from products of AA in the lipooxygenase ("LPO") pathway, a significant buildup of AA occurs which can be most easily relieved from a redox viewpoint by creation of isoprostanes.

Such excess production has implications for the lipooxygenase metabolic pathway. The evidence for this lipooxygenase pathway effect is seen in isoprostanes which are prostaglandin-like compounds which are formed by free radical catalysed peroxidation of arachidonic acid esterified in membrane phospholipids (Neurochem Res 2000 Oct;25(9-10):1357-64). Unfortunately for the cancer cell, isoprostanes are indicators of damage to membrane phospholipids. Arachidonic acid (AA) is esterified in the membrane phospholipids, and when oxidized, isoprostanes are the end-product. The peroxidation products are monitored by measuring the isoprostanes and lipid peroxides. For a rapidly dividing cancer cell in which membrane synthesis is critical, the increase in arachidonic acid and its potential damage to membrane phospholipids has negative implications for replication success. The rise in isoprostane levels shows that oxidation of excess arachidonic acid is occurring. This is one mechanism for the damage from excess arachidonic acid that may be seen with the use of the COX-2 inhibitors and contributes to explaining the toxic effect of a COX-2 inhibitor, especially in rapidly dividing cells. However, presence of the isoprostane in the blood or urine would signal an upper limit has

been reached of the COX-2 inhibitor above which the risk of kidney or liver damage may increase.

Lipid peroxidation is best characterized as a series of chain breaking reactions in the lipid bi-layer at the membrane which inhibits the proper growth of proteins. The membrane is rendered more porous and susceptible to degeneration, or to penetration by other molecules in the body's immune system. Analogously, lipid peroxidation by heat occurs in an egg white when heated. In the body, and as is desired in cancer cells, such lipid peroxidation occurs chemically.

The HMG-CoA reductase inhibitor simvastatin has been shown to produce positive effects in the endothelial lining of blood vessels even independent of its lipid lowering effects. Animals with high cholesterol diets who exhibited continued high serum cholesterol who were administered simvastatin demonstrated a lower rate of production of F(2)-isoprostanes and thiobarbituric acid-reactive substances (TBARS), markers of oxidative stress, than animals who were not treated with simvastatin and maintained on a high cholesterol diet. *Arterioscler Thromb Vasc Biol* 2001 Jan;21(1):122-8). Simvastatin is an analog of lovastatin, which are both statins produced from *aspergillus terreus*.

The presence of the HMG-CoA reductase inhibitor may contribute to moderating the effects of lipid peroxidation produced in the normal cells moderating production of isoprostanes.

While a protective effective may not seem facially desirable, consideration needs to be made of the selectivity which occurs. The cancer cell metabolic pathways which result in the higher expression of COX-2 in cancer cells, which the invention proposes to inhibit, suggest that cancer cells utilize COX-2 in a meaningful way, a conclusion supported by the apparent partial efficacy of COX-2 inhibitors against cancer. In order to obtain COX-2, cancer cells have a signaling system to stimulate the precursor of COX-2, which is arachidonic acid. Normal cells which do not have a similar need for COX-2 apparently do not have such a signaling system.

For a cancer cell which under normal replication conditions will experience a more rapid genesis of lipid peroxidation products from membrane synthesis, the inventors surmise that the partial protective effect of a statin to slow the rise in isoprostane levels is selectively insufficient to protect the cancer cell from excess arachidonic acid, while acting protectively in normal cells. As a corollary, whatever offsetting benefit the statin may have against the lipooxygenase pathway

products is not sufficient to overcome either the toxic effects of excess arachidonic acid, nor to offset the cholesterol synthesis inhibition occurring in the cholesterol synthesis pathway with respect to production of mevalonate and occurring with respect to excess geraniol as a result of interference with squalene conversion to cholesterol.

Thus, there is a selective effect of increased toxic metabolites when a COX-2 inhibitor is administered as evidenced by increased isoprostane levels, with end products that have primary toxicity to cancer cells from excess lipid peroxidation and the LTEB₄. Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, publ by Ciba-Geigy (1986), p. 25-27, 142-147.

Testing of isoprostanes and TBAR's can be used to determine if excessive amounts of lovastatin or any statin are being used and as an indicator of the level of lipooxygenase peroxidation effects.

Another product that can result from increased arachidonic acid is 5-HETE which has been implicated in prostate cancer. Miller et al, "5-HETE Congeners as Modulators of Cell Proliferation," Bioorg. Med. Chem. Ltr. 10(17): 913-916 (Sep. 4, 2000). It is poorly disposed of. However once saturated, it will cause increased arachidonic acid buildup if arachidonic acid buildup is being artificially stimulated such as by a COX-2 inhibitor. Further evidence of this effect of increased AA concentration is shown from experiments with γ -linoleic acid which is the precursor of arachidonic acid through the formation of dihomo- γ -linoleic acid ("Metabolism at a Glance", Salway, 2nd edition, BlackWell Sciences, UK pg. 86). Conjugated linoleic acid (CLA) is prone to oxidation, and it has been suggested that increased oxidation of lipids may contribute to an anti-tumorigenic effects of this agent. Clin Sci (Colch) 2000 Dec;99(6):511-6. There, researchers followed levels of 8-iso-prostaglandin F(2 α) (8-iso-PGF(2 α)), a major isoprostane, and of 15-oxo-dihydro-PGF(2 α), a major metabolite of PGF(2 α), (collectively referred to as isoprostanes) and tested their levels, as indicators of non-enzymic and enzymic arachidonic acid oxidation respectively after dietary supplementation with CLA in middle-aged men (mean age 53 years) with abdominal obesity for 1 month in a randomized controlled trial. Thus, the addition of CLA to the diet of people undergoing metabolic cancer therapy with a Hmg-CoA and a COX-2 inhibitor would result in an enhanced effect by

increasing the lipid oxidation effect of the isoprostanes, and shows the creation of excess arachidonic acid has antitumorigenic effect as predicted by the inventors.

Using the isoprostane levels as indicators, the treatment dose of the COX-2 inhibitor can be maximized to give the maximum tolerated dose for use in cancer therapy without creating excessive systemic toxicity. More lipid oxidation activity indicates increased oxidative stress, usually a characteristic of cancer activity. A long-term falling level of isoprostanes will mean for COX-2 expressing cancers that there is relatively less cancer risk. An ELISA test for isoprostane level is available from Cayman Chemical Company, 11800 E. Ellsworth Rd., Ann Arbor, Michigan.

For a membrane-impaired cancer cell, receptors and transport molecules for materials needed for cell survival tend to be overloaded and the cell does not function properly, much less have much chance of replicating accurately with an intact membrane. Additionally, in this invention, the shift in concentration caused by excess ubiquinones toward semiquinone triggers increased lipid peroxidation. Nohl, "Antioxidant-derived prooxidant formation from Ubiquinol," Free Radical Biol. Med. 25(6): 666-675 (Oct. 1998). While the statin can ameliorate the tendency to lipid peroxidation, which is why a lower dose is preferred, it need only be sufficient to impair cholesterol synthesis, and there remain sufficient lipid peroxidants to damage cancer cells while normal cells are slightly protected.

The presence of ubiquinones in normal cells with adequate glutathione does not materially change their characteristics; however in cancer cells, the excess ubiquinones in combination with the already nascent tendency to express lipid peroxidation sufficiently the weakens the cells to expose them to immune system attack, a tendency not overcome by the presence of glutathione which is less active in the more anaerobic environment of a cancer cell.

Lovastatin and its inhibition of farnesyl pyrophosphate and geranylgeranylpyrophosphate

Lovastatin has another inhibitory effect which has implications for both cholesterol synthesis, ubiquinone concentration, and farnesyl pyrophosphate concentration. "Lovastatin, an HMG-CoA reductase inhibitor that inhibits the biosynthesis of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GPP), is used routinely as a positive control for inhibition of processing of both geranylgeranylated and farnesylated proteins [citations omitted]." A. Vogt et al, "A Non-peptide Mimetic of Ras-CAAX: Selective inhibition of Farnesyl Transferase and Ras Processing," 270(2) J. Biol. Chem. 660-664 (2000). In addition to additional direct cholesterol inhibition, Salway, *Metabolism at a Glance* at 88-89 (Blackwell Science 2nd ed. 1999), the effect of any FPP inhibition is to directly inhibit production of dolichols, which has implications for dolichol phosphate which affects messenger RNA transcription. Since cancer cells are attempting to replicate, a selective effect on cancer cells by affecting messenger RNA is achieved. Lehninger on Biochemistry at 1059, 3rd ed. GPP inhibition likely has the same effect as post-lanosterol cholesterol cycle inhibition in that additional energy must be used to overcome inhibitory effects. The Vogt article also notes that cysteine is important in ras oncogene activation. This teaches away from the benefits of glutathione pathway protection, but the inventors suggest that the combination of diversion of glutathione pathway resources to stabilize other adversely affected metabolic pathways of a cancer cell is likely sufficient in combination with FPP and GPP inhibition to interfere with cell replication. What FPP is generated will be diverted to enhance cholesterol synthesis making it less available for ras oncogene activation in conjunction with cysteine.

Lipid peroxidation and reactive oxygen and nitrogen species

The article entitled "Reactive Oxygen and Nitrogen Species: Efficient, Selective, and Interactive Signals During Intercellular Induction of Apoptosis; Georg Bauer, Abteilung Virologie, Institute for Medizinische Mikrobiologie und Hygiene, Universität Freiburg, D-79104 Freiburg, Germany; Anticancer Research 20: 4115-4140 (2000) contains a comprehensive discussion of the interplay of reactive nitrogen species and oxygen species with apoptosis. See also, Bolanos, Nitric Oxide, Mitochondrial Function and Excitotoxicity, Methods Findings Exp. Clin Pharmacol, 2000, 22(6): 375-77. The Bauer article sets out a series of chemical equations related to processing of reactive oxygen and nitrogen species.

The issue is what about a selective COX-2 inhibitor, the overproduction of ubiquinones, and the interference with mitochondrial respiration, assuming an adequate supply of glutathione, enables the invention to be effective. We have already recognized that additional energy will be needed to generate cholesterol both because of HMGCoA inhibition and squalene-to-cholesterol synthesis inhibition.

The answer from the Bauer article focuses on the tendency of excess NO and OH species, particularly in their free radical forms, to accelerate lipid degeneration.

As stated previously, lipid peroxidation is best characterized as a series of chain breaking reactions in the lipid bi-layer at the membrane which inhibits the proper growth of proteins. The membrane is rendered more porous and susceptible to degeneration, or to penetration by other molecules in the body's immune system.

In an article entitled "Antioxidant-Derived Prooxidant Formation from Ubiquinol...", Nohl et al, Free Radical Biol. Med. 25(6): 666-75 (Oct. 1998) set forth that "Our studies on the antioxidant activity of ubiquinol in peroxidizing lipid membranes demonstrate the existence of ubisemiquinone ($SQ\cdot$) as the first reaction product of ubiquinol. A reaction of $SQ\cdot$ derived from the localization allows an access of protons and water from the aqueous phase to $SQ\cdot$ [,] a prerequisite earlier found to trigger autoxidation. Superoxide radicals emerging from this fraction of autoxidizing $SQ\cdot$ form H_2O_2 by spontaneous dismutation. $SQ\cdot$ not involved in autoxidation may react with H_2O_2 . Transfer of the odd electron to H_2O_2 resulted in $HO\cdot$ and $HO-$ formation by homolytic cleavage. An analogous reaction was also possible with lipid hydroperoxides which

accumulate in biological membranes during lipid peroxidation. The reaction products emerging from this reaction were alkoxyl radicals. Both $\text{HO}\cdot$ and alkoxyl radicals are strong initiators and promoters of lipid peroxidation.” *Id.* Abstract to “Antioxidant-Derived Prooxidant Formation from Ubiquinol...,” Nohl et al, *Free Radical Biol. Med.* 25(6): 666-75 (Oct. 1998).

To summarize the important postulates of Bauer with respect to their interrelationship with this invention, first, $\cdot\text{NO}$ in the presence of $\text{O}_2\cdot^-$ forms peroxynitrite $\text{ONNO}\cdot^-$. This is not stable. Interestingly, this peroxynitrite is not a free radical. However, in the acidic environment of a cancer cell, there is a propensity to form “the instable peroxynitrous acid.... Peroxynitrite has the potential for lipid peroxidation (no formula shown [in the article]). *Id.* at 4119. “Singlet oxygen, formed after interaction of hydrogen peroxide and peroxynitrite [f.n. omitted] has an extremely short half-life and has the potential for lipid peroxidation[f.n. omitted]. Nitric oxide, though being a free radical shows a long range of action and rather low toxicity. It inhibits lipid peroxidation and caspases. Interaction of nitric oxide with superoxide anions causes the formation of peroxynitrite, a potent lipid peroxidant and apoptosis inducer.” *Id.* at 4116. There are a series of reactions, several of which involve glutathione.

The positive empirical results from the patients on which this invention was tested indicate that peroxynitrite acts as a strong oxidant when increased there is cytokine production. With the increase in ubiquinones causing increased production of superoxide, relatively more of which is available in cancer cells to cause peroxynitrite formation at appropriate pH, the peroxynitrite can cause direct damage to proteins. The second and third reactions discussed are degeneration by homolysis, $\cdot\text{OH} + \cdot\text{NO}_2$, or heterolysis degenerating to $\cdot\text{OH} + \text{NO}^+$. Even the fourth reaction, ONOOH to ONOOH^+ is troublesome for a cancer cell because of the creation of a more acidic environment.

Equally apparent from the equations is the importance of glutathione in detoxification of radical species and prooxidant species such as $\text{ONNO}\cdot^-$. Glutathione is thought to have a protective effect in a number of instances. However, as postulated, glutathione functions more actively in an anaerobic environment. As a cancer cell’s energy needs are stressed by a COX-2 inhibitor, more anaerobic respiration occurs, lowering the pH of the cancer cell slightly, shifting even glutathione reactions away from oxidation to more benign species and generating more free

radical damage and accelerating lipid peroxidation. While cancer cells having complete angiogenesis will be less affected by these reactions, the inclination to apoptosis and the degeneration of angiogenic species either as a result of the death of a cell, or the waste of energy in the tumor to generate unutilized angiogenesis both inhibit the cancer cell's growth. Bauer notes that his key reactions occur early in tumor development prior to angiogenesis, Bauer, 20 AntiCancer Research at 4115, a result consistent with the inventors' clinical observation that cancer is not eliminated but retarded or managed by the invention.

The presence of ubiquinones in normal cells with adequate glutathione does not materially change their characteristics; however, in cancer cells, the excess ubiquinones in combination with the already nascent tendency to express lipid peroxidation sufficiently weakens the cells to expose them to immune system attack, a tendency not overcome by the presence of glutathione which is less active in the more anaerobic and more acidic environment of a cancer cell.

Metal complex ions and glutathione

Another aspect to consider is that H_2O_2 has a potential rescuing effect for cells to blunt NO mediated apoptosis at high cell density. A primary generator of H_2O_2 is glutathione reactions which in a normal cell environment remove hydroxyl radicals, and nitric oxide radicals. In conjunction with metal ions, particularly copper, zinc and magnesium, in glutathione competent cells, the H_2O_2 breaks down into water. As explained by Bauer, cells are in a sense rescued from apoptosis in that situation. In cells not so equipped, which would include a number of cancer cells in a tumor, more hydroxyl radicals are generated, and there is not a rescue from apoptosis. The fact that, as explained by Bauer, H_2O_2 is a far-ranging species that can intercept NO species far from a cell membrane may explain for small cell cancers, where intercellular range is less of an issue, the relatively toxicity and tumorigenicity of those cancers where the range of operation is less of a factor in what self-protective mechanisms the body has to battle the cancer. The presence of HOCl cannot be ignored which Bauer believes interacts with H_2O_2 to generate non reactive molecules such as oxygen, water, chloride anions and protons. Bauer, 20 AntiCancer Research 4115-4140, generally.

Notably, however, Bauer remarks that the speed of reaction is not significant unless reaction number 3 [$HOCl + H_2O_2 \rightarrow O_2 + H_2O + Cl^- + H^+$] is blocked by SOD which is more likely

to occur in the COX-2 inhibitor affected cancer cell because of the shift in electron concentration generating more potential O_2^- . Bauer, 20 AntiCancer Research 4118-19. As the kinetics for this reaction to occur become more favorable, SOD, which has been stably attached to Mn, Zn or Cu, is detached as the reaction proceeds and the SOD performs its catalytic function. The resultant free radical metal ion generated, in the presence of HOCl, accelerates lipid peroxidation. Bauer, Anticancer Research 20: 4115-4140 (2000) at 4118-19.

Glutathione (GSH), a critical element in immune system function, unquestionably has some positive effects for the cancer cell because it can scavenge free radicals. Yet this is needed in all cells. Glutathione does have a favorable effect on cancer cells through its protection of the disulfide bridges. Protection of disulfide bridges inhibits lipid peroxidation therefore protecting protein structure, particularly tertiary and quaternary structures. "Glutathione probably helps maintain the sulfhydryl groups of proteins in the reduced state and the iron of heme in the ferrous (Fe^{2+}) state, and it serves as a reducing agent for glutaredoxin in deoxyribonucleotide synthesis (see Fig. 2-37 [in source]). Its redox function is also used to remove toxic peroxides formed in the normal course of growth and metabolism under aerobic conditions: $2GSH + R-O-O-H$ to $GSSG + H_2O + R-OH$." Lehninger, Principles of Biochemistry (3rd ed. 2000) at 842. As is apparent from the quotation, any effect on glutathione supply, such as failure to remove toxic peroxides, or lack of presence for deoxyribonucleotide synthesis because of competitive consumption to maintain homeostasis in cancer cells has serious implications for cell division and replication, which is the lifeblood and toxicity of cancer.

Glutathione, however, will be slightly less present in the acidic environments of cancer cells. Glutathione is gamma-Glu-Cys-Gly. The COO^- ion on the end of the chain will be more present and a more favored species in a less acidic environment. The more acidic environment of anaerobic glycolysis in cancer cells causes a shift to moderately lower relative glutathione concentrations, and consequently less protection from apoptotic free radical reactions.

The implications of metal ion reactions and glutathione, as seen in the Bauer equations, Anticancer Research 20: 4118-19 (2000), are that glutathione absorption in stabilizing free radicals to convert them to H_2O_2 has implications in coincidentally affecting the reaction kinetics of superoxide dismutase (SOD) and affecting the metal ion chemical reactions illustrated by Bauer

under "M" at Anticancer Research 20: 4118.

This invention does not propose to be *prima facie* a cancer cure, but rather a *prima facie* cancer manager. The competitive consumption of energy to overcome cholesterol synthesis, to overcome interference with mitochondrial respiration, and the competitive consumption of GSH to thwart lipid peroxidation, and to rescue cancer cells from reactive oxygen and nitrogen species either weakens existing cells, weakens newly generated cells (which may then undergo self-apoptosis) or inhibits membrane and DNA synthesis or all of these. The inherent characteristics of replicating cancer cells and the necessary anaerobic enhancement to their energy processes enable the invention to selectively attack cancer cells while normal cells and their homeostatic processes can protect the mammalian organism which the inventors desire to preserve. Moreover, the administration of the compounds in the invention enable the organism to achieve the senescence which cancer cells have attempted to elude through a variety of mechanisms that the body in many instances is helpless to resist. The use of HOCl, and the application of NO⁻ and OH⁻ is the usual means to achieve senescence, and the invention enables proper operation of that mechanism.

NADPH concentration, COX-2 inhibitors and apoptosis

A corollary effect of the inhibition of creation of cholesterol relates to the shifting of equilibrium toward to squalene and a higher concentration of NADPH+H⁺ as a result of the action of the COX-2 inhibitor. As remarked by Bauer, what is at issue is high speed bursts of adjacent NO/O₂⁻ activity which can damage membranes and cells. The marginal and momentary increase in NADPH +H⁺ has a series of contradictory effects. Exterior to the mitochondria, increased levels of NADPH can be seen to slow reactions in the pentose phosphate pathway, namely in the transition from glucose-6-phosphate to ribulose 5-phosphate. Selective shifts in this pathway affect glucose-6-phosphate, though perhaps only mildly. NADPH concentration shifts also slow the conversion of malate to pyruvate, a precursor to acetyl CoA, a precursor to cholesterol, a possible positive in inhibiting cancer cell membrane synthesis. Another effect is a buildup of lactic acid with concomitant cytotoxic effects for cells unable to tolerate increased acidity. Salway, *Id.* at pp. 49, 60. Salway remarks on this shift indirectly, noting that "during re-feeding after fasting, glucose is metabolized anaerobically to lactate by muscle even though the

conditions are aerobic. This is because, immediately after refeeding, the high ratio of acetyl CoA to pyruvate caused the lingering B-oxidation of fatty acids, results in pyruvate dehydrogenase remaining inhibited... Consequently, glucose in muscle is metabolized to pyruvate which is reduced to lactate. Salway, *Metabolism at a Glance* (Blackwell Science Oxford 1999) at p. 60. A similar effect occurs for cancer cells affected by an HMG-CoA reductase inhibitor. The increased acetyl CoA buildup in cancer cells causes increased lactate production. Salway, *Id.* at 51. That lactate tends to slightly acidify the cancer cell, which has implications in induction of apoptosis. In normal cells, homeostasis is such that an Acetyl CoA imbalance is not toxic on refeeding after starvation because the Acetyl CoA /CoA precursor ratio is not affected.

In cancer cells where increased Acetyl CoA has to be present to overcome the inhibition of synthesis of cholesterol, there is a transient increase of acidity, favoring the reaction of peroxynitrite to NO⁻ and OH⁻ apoptotic free radicals.

NADPH is also implicated in the presence of NADPH oxidase in the generation of free electrons leading to O₂⁻ species. As explained by Bauer, these are implicated in induction of apoptosis. In cancer cells demanding cholesterol, as the reactions of intermediates from squalene and lanosterol to cholesterol are slowed by a selective COX-2 inhibitor, there are momentary increases in NADPH. This has apoptotic effects selective to cancer cells as opposed to normal cells.

The discussion above, and the article by Bauer, "Reactive Oxygen and Nitrogen Species: Efficient, Selective, and Interactive Signals During Intercellular Induction of Apoptosis," Anticancer Research 20: 4115-4140 (2000), amply confirm and correlate with the observations of Ellerby et al, Measurement of Cellular Oxidation, Reactive Oxygen Species, and Antioxidant Enzymes during Apoptosis, 322 Method in Enzym. 413 (Academic Press 2000), Bortner, Volume Regulation and Ion Transport during Apoptosis, 322 Method in Enzym. 421 (Academic Press 2000) regarding the apoptotic cascade that can be triggered by the osmotic pressures on a cancer cell as it struggles to maintain chemical homeostasis. The chemical kinetics and reactions confirm the clinical observations with respect to the invention. On balance, the tendency of the combinations in the invention is to selectively disfavor cancer cells based on the inventor's empirical observations. The inventors also note that the explanation of pharmacokinetics is

consistent with the tendency of tumors, once expanded to have a mass of necrotic tissue within them (another complicating factor of cancer), suggesting that glutathione activity, accumulation of wastes and apoptosis are natural mechanisms of cancer cells which the science of this invention attempts to exploit at an earlier stage of cancer cell development in order to manage tumor activity.

Metal complex interactions:

The interaction of nitrous oxide and reactive oxygen species is one of the most important apoptotic triggers in anti-tumor activity. As previously discussed, COX-2 has two interactions with mitochondrial respiration and ATP utilization, one direct and one indirect. The direct interaction is the lipophilic/hydrophilic orientation which can inhibit the F0/F1 channel in complex IV. Salway, *Metabolism at a Glance* at 14-15 (Blackwell Science 2nd ed. 1999). The indirect interaction is the increased relative production of ubiquinone as a result of the inhibition of cholesterol demethylation.

Metal ions have the capacity to catalyze, in conjunction with superoxide dismutase (SOD), generation of compounds influential in apoptotic process. Bauer, *Reactive Oxygen and Nitrogen Species: Efficient, Selective, and Interactive Signals During Intercellular Induction of Apoptosis, Anticancer Research* 20: 4115-4140 (2000) at 4118. See also, Bolanos, *Nitric Oxide, Mitochondrial Function and Excitotoxicity, Methods Find Exp. Clin. Pharmacol.* 2000 22(6): 375-77.

Wink and Mitchell, in *Chemical Biology of Nitric Oxide: Insights into Regulatory, Cytotoxic, and Cytoprotective Mechanisms of Nitric Oxide, Free Radical Biol. & Med.* 25(4): 434-456, Sept. 1998, suggest that changes in NADPH oxidase and nitric oxide levels can affect the availability of iron in a cell. This has catastrophic implications for a selectively affected cancer cell. *Id.* at 447.

Selective disturbance of metal ion interaction in cancer cells will enhance any probability of apoptosis engineered by other metabolic mechanisms.

Particular efficacy for androgen responsive prostate cancer:

The interference with cholesterol synthesis has a further implication for prostate cancer because cholesterol is a precursor to testosterone which has been shown to be an important

contributor to prostate cancer. Androgen suppression is a standard therapy for several lines of prostate cancer, but tends to have time limitations before certain cells become androgen insensitive. Prostate Cancer: Biology, Genetics, and the New Therapeutics p. 92 and Ch. 19 at 327-340 (Humana Press, Totowa NJ 2001). While the body has other offsetting mechanisms to continue to signal for generation of androgen, there is at least a partial biochemical effect resulting from interference with cholesterol synthesis.

The first object of this invention proposes to selectively interfere with the production of cholesterol in two places in a way that impairs the energy cycle of all cells but which normal cells can overcome because they need less energy to survive because they are not dividing, but in a way that has a disproportionate and damaging effect on cancer cells which must replicate, or the cancer will not spread. This object takes advantage of the cancer cell's requirement for cholesterol causing biochemical signaling for cholesterol if not adequate to meet the replicating cancer cell's needs.

A second object is to selectively modify a biochemical cycle that targets inflammatory mechanisms in the body. One of the most damaging aspects of cancer cells is that they trigger an extended inflammatory response in the body. Prostaglandins are some of the most important signals to cause inflammatory responses. The biochemical cycle that we propose to selectively inhibit is an important cycle that converts arachidonic acid to several forms of prostaglandins. That cycle is the cyclooxygenase or COX cycle.

Biochemical cycles have many intermediate steps in them and the intermediate compounds are known as "intermediates." One of those intermediates in the cyclooxygenase cycle is prostaglandin H₂ synthase, which has two forms: COX-1 and COX-2. COX-1 is known as a housekeeping substance which helps generate substances that protect the stomach. Ding et al, "Blockade of Cyclooxygenase-2 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells, vol. 20 AntiCancer Research, 2625-2632 (2000). Aspirin inhibits COX-1 and therefore, because it inhibits a substance that protects the stomach, often has abdominal side effects. Recently, substances have become available that selectively inhibit COX-2 enzymes

over COX-1 enzymes. COX-2 enzymes regulate pain, inflammation and fever, i.e. inflammatory mechanisms.

The COX-2 inhibitors in this invention interfere with the transformation of a substance called squalene to cholesterol. There are numerous intermediates from squalene to cholesterol.

Earlier in the biochemical cycle that produces cholesterol is a substance called Acetyl-CoA enzyme. It is converted to an intermediate called mevalonate by an enzyme called 3-hydroxy-3-methylglutamate-CoA reductase ("HMG-CoA"). Recent pharmaceutical advances have produced a number of substances that inhibit the activity of HMG-CoA and slow the production of cholesterol. HMG-CoA inhibitors have been used and are claimed to be used to reduce cholesterol to slow various blood vessel and related heart disease problems which we generally refer to as cardiovascular disease.

A third object of this invention is to utilize the more optimal function of cystine in the pH balance of a normal cell than in the lower pH of a cancer cell. The administration of cystine, enhances the body's immune system benefitting the total body disproportionately to any benefit cystine administration may have for a cancer cell.

A fourth object is to utilize cystine to ameliorate the negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA inhibitors, both as a combination and individually. The invention is useful for the amelioration of negative gastric and hepatic effects in combination with and caused by a COX-2 inhibitor and for the amelioration of negative hepatic and renal effects in combination with and caused by an HMG-CoA inhibitor.

A fifth object is to restore balance to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia.

In sum, the premise of this invention for cancer is that the cancer cells divide rapidly, that they have significant anaerobic glycolytic processes, and that the body is one large biochemical machine in which we can play to the strength of our body to the detriment of the cancer cell.

For other conditions, the restoration of biochemical homeostasis, or encouragement of the body's restoration of biochemical homeostasis is the objective of the invention.

Background as to Neurological conditions:

In association with migraines, increased serotonin metabolites, platelet levels of serotonin or its precursor, 5-HT (5-hydroxy tryptamine), are observed. The reason for the head and face manifestations in a migraine relate to the fact that receptors for 5-HT are located on the 5th cranial nerve. AMA Med Sci. course on Migraine: www.ama-assn.org/med-sci/course/migraine/m1path.htm (Feb. 16, 2001). NSAID's are noted to potentially block neurogenic inflammation.

A selective COX-2 inhibitor offers the opportunity to preserve the positive function of COX-1 while relieving inflammation. The cystine ameliorates the negative effects. There is a notation of response to celecoxib, a selective COX-2 inhibitor. Neurology 2000 vol. 55(2): 316. Indomethacin, a less selective COX-2 inhibitor has been shown to have positive effect. Headache 2000 vol 40(6): 483-6.

The advantage is that cystine shifts anti-inflammatory response to a higher Th1/Th2 ratio, as well as serving as a potential selective COX-2 inhibitor. [PMS-mefenamic acid, prostaglandin synthesis inhibitor]. Eur. J. Med. Research 2000 vol 5(4): 176-82.

Carotidynia was controlled in a case report by indomethacin. Rev. Neurology 1999 vol 29(11):54-5.

PREFERRED MODE OF INVENTION:**Viral diseases and conditions:**

The inventors propose use of a selective COX-2 inhibitor and cystine for anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C. Also because of the need for membrane penetration, an HMG-CoA reductase inhibitor, Penzak SR, "Safety and Efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection," Pharmacotherapy 2000 vol 20(9): 1066-71 (Sept. 2000).

Neurological conditions:

The proposed efficacy is for treatment to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate

neurodegenerative diseases aggravated by inflammatory condition and carotidynia. The inventors propose the addition of cystine (as later defined) and a selective COX-2 inhibitor as related in Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled "Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease" (claiming a combination of a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events and a method of using a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events), and Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled "Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions" (proposing the utilization for an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor to treat, prevent or reduce the risk of acute coronary ischemic syndrome, thrombosis, and related vascular problems). The inventors propose the addition of cystine to a selective COX-2 inhibitor to enhance its anti-inflammatory effect and to moderate the potential negative effects of a COX-2 inhibitor, particularly negative gastrointestinal effects, negative liver effects or negative kidney effects. The term patient or body or reference to humans is utilized for convenience, but includes all mammalian patients or bodies. The inventors also propose to use a selective COX-2 inhibitor alone for the purpose, though less efficacious than in combination with cystine. In combination with magnesium sulfate, a more efficacious result can be achieved in certain instances. Based on an article entitled, "Efficacy of Intravenous Magnesium Sulfate in the Treatment of Acute Migraine Attacks." Demirkaya S, et al, Headache 2001 Feb;41(2):171-177, the authors conclude that not only the side effects of severe or moderate migraine headaches, but also the pain were eliminated or notably diminished after administration of 1gm Magnesium in the preferred amount, such as 1gm Magnesium sulfate intravenously over 15 minutes. Only mild side effects which did not necessitate termination of treatment were observed. The placebo patients were subsequently treated with Magnesium sulfate and also all responded. Twenty-six patients out of thirty (86.6%) had mild side effects which did not necessitate discontinuing treatment. The invention proposes the administration of therapeutic doses of a pharmaceutically acceptable form of magnesium sulfate, and also pharmaceutically acceptable forms of magnesium chloride,

pharmaceutically acceptable forms of magnesium glycinate, and pharmaceutically acceptable chelated forms of magnesium. Such dose in the preferred mode of a magnesium would be an amount to achieve a concentration equivalent to 1 gm magnesium sulfate administered intravenously over 15 minutes.

Reflecting the pharmacokinetics in the applications referenced in this application, the inventors propose the composition of a selective COX-2 inhibitor and cystine to reduce and hopefully the inflammation associated with migraine headaches. Further, the composition will slow the neurogenerative effects of inflammation associated with neurogenerative diseases such as Alzheimer's disease. The method of administration of these two substances simultaneously or stepwise, and the method of manufacturing them together is claimed.

The preferred dose is at the lower end of the therapeutic window, sufficient to achieve an ameliorative effective. The therapeutic window should be considered lower if chronic use is contemplated.

One of the most important, but underestimated and understudied biochemical cycles in the body is the glutathione cycle. Recently, literature is beginning to recognize the importance of this cycle as the central cycle in determining a body's ability to fight disease. A substance called L-cystine, generally called cystine, and other intermediates in the glutathione cycle called cysteine, and substances convertible into cystine and cysteine such as N-acyl-cysteine, are proposed as part of this invention to enhance immune system competency. Recent literature Fosslien [from Univ. of Chic.] "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (2000) (published in late Oct./Nov.), suggests that a cystine analog, N-acetyl-cysteine (which is converted to cystine and cysteine, has selective COX-2 inhibition properties.

In a recent article in 1998, anti-oxidants (any substance in low concentration that prevents oxidation of a substrate) were referenced. The reference mentioned TROLOX, which is generally perceived as toxic, and NAC, which can be utilized by a human. These were stated to decrease prostaglandin production and increase apoptosis. Anti-oxidants are cited as decreasing the COX-2 expression at the transcriptional level. Chinery et al, "Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells", Cancer

Research 1998 Jun 1;58(11):2323-7 . Initially, the authors observed that "increased expression of cyclooxygenase (COX) and overproduction of prostaglandins (PGs) have been implicated in the development and progression of colorectal cancer (CRC)", and that "reactive oxygen intermediates play a role in tumor cell growth regulation and expression of the inducible COX, COX-2,." The authors then "evaluated the effects of various antioxidants on COX expression and cellular growth in the human CRC cell line HCA-7. The antioxidants pyrrolidinedithiocarbamate (PDTC), N-acetylcysteine, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, (Trolox), and U74006 decreased PG production, intracellular redox status, and cellular growth in a concentration-dependent manner. The decrease in cellular growth was associated with the induction of apoptosis. Unlike the selective COX inhibitors 1-[(4-methylsulfonyl)phenyl]-3-trifluoromethyl-5-[(4-fluoro)phenyl]pyrazole (SC 58125) and (2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (NS 398) that inhibit COX-2 catalytic activity, these antioxidants decreased COX-2 expression at the transcriptional level. Combined treatment of HCA-7 cells with PDTC and SC 58125 resulted in an additive decrease in PG levels and anchorage-dependent and -independent growth. Furthermore, whereas antioxidants or SC 58125 reduced tumor growth in vivo, coadministration of PDTC and SC 58125 resulted in actual tumor regression. These results suggest that combined therapy with NSAIDs and antioxidants might be useful in the prevention and/or treatment of CRC." The article does not propose the use of an HMG-CoA inhibitor and cystine, nor the use of a strongly selective COX-2 inhibitor currently being marketed for human consumption such as rofecoxib, celecoxib or etoricoxib in conjunction with cystine. Many NSAID's are COX-1 inhibitors, which is not as desirable, and a positive ratio of COX-2 inhibition to COX-1 inhibition is important to the invention. Importantly, the article does ratify the thesis of this invention that cystine has selective COX-2 inhibition effects. No mention is made of any applicability other than cancer.

The invention is not meant to be limited to the disclosures, including best mode of invention herein, and contemplates all equivalents to the invention and similar embodiments to the invention for humans and mammals and veterinary science. Equivalents include all

pharmacologically active racemic mixtures, diastereomers and enantiomers of the listed compounds and their pharmacologically acceptable salts.

CLAIMS:

1. A combination for treatment of conditions exhibiting inflammatory characteristics including viral disease, atherosclerosis, vascular disease, HIV, neurodegenerative conditions, and cancer, comprising:
a selective COX-2 inhibitor and cystine
2. The combination according to claim 1, further comprising:
a therapeutic dose of selenium.
3. The combination according to claim 2, further comprising:
a therapeutic dose of vitamin C.
4. The combination according to claim 3, further comprising:
a therapeutic dose of vitamin E.
5. The combination according to claim 1, further comprising:
an HMG-CoA reductase inhibitor.
6. The combination according to claim 5, further comprising:
a therapeutic dose of selenium.
7. The combination according to claim 6, further comprising:
a therapeutic dose of vitamin C.
8. The combination according to claim 7, further comprising:
a therapeutic dose of vitamin E.
9. A combination for treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia comprising:
a selective COX-2 inhibitor, a pharmaceutically acceptable magnesium enhancing compound selected from the group of magnesium sulfate, magnesium chloride, magnesium glycinate, and chelated forms of magnesium and cystine.
10. The combination according to claim 9, further comprising:
a therapeutic dose of selenium.

11. The combination according to claim 10, further comprising:
a therapeutic dose of vitamin C.
12. The combination according to claim 11, further comprising:
a therapeutic dose of vitamin E.
13. A method of treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C, of treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems, of treatment of cancer, and of treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia, comprising the following steps:
administering a selective COX-2 inhibitor; and
administering cystine.
14. The method of treatment according to claim 13, further comprising the following step:
Administering a therapeutic dose of selenium.
15. The method of treatment according to claim 14, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
16. The method according to claim 15, further comprising the following step:
Administering a therapeutic dose of Vitamin E.
17. The method of treatment according to claim 13, further comprising:
Administering a therapeutic dose of lipoic acid.
18. The method of treatment according to claim 17, further comprising the following step:
Administering a therapeutic dose of selenium.
19. The method of treatment according to claim 18, further comprising the following step:
Administering a therapeutic dose of Vitamin C.

20. The method according to claim 19, further comprising the following step:
Administering a therapeutic dose of Vitamin E.
21. The method of treatment according to claim 13, further comprising the following step:
Administering a therapeutic dose of an HMG-CoA reductase inhibitor.
22. The method of treatment according to claim 21, further comprising the following step:
Administering a therapeutic dose of selenium.
23. The method of treatment according to claim 22, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
24. The method of treatment according to claim 23, further comprising the following step:
Administering a therapeutic dose of Vitamin E.
25. The method of treatment according to claim 26, further comprising:
Administering a therapeutic dose of lipoic acid.
26. A method of treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C, of treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems, of treatment of cancer, and of treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia, comprising the following steps:
administering a selective COX-2 inhibitor selected from the pharmaceutically acceptable group of compounds having silibinin as the active ingredient; and
administering cystine.
27. The method of treatment according to claim 26, further comprising the following step:
Administering a therapeutic dose of selenium.
28. The method of treatment according to claim 27, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
29. The method according to claim 28, further comprising the following step:

Administering a therapeutic dose of Vitamin E.

30. A method of treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C, of treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems, of treatment of cancer, and of treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia, comprising the following steps:
 - administering a selective COX-2 inhibitor selected from the pharmaceutically acceptable group of compounds having silibinin as the active ingredient;
 - administering cystine.
 - and administering an HMG-CoA reductase inhibitor having a statin, including lovastatin, as its active agent.
31. The method of treatment according to claim 30, further comprising the following step:
Administering a therapeutic dose of selenium.
32. The method of treatment according to claim 31, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
33. The method according to claim 32, further comprising the following step:
Administering a therapeutic dose of Vitamin E.
34. The method of treatment according to claim 33, further comprising:
Administering a therapeutic dose of lipoic acid.
35. A method of treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia, comprising the following steps:
 - administering a selective COX-2 inhibitor; and

administering a pharmaceutically acceptable magnesium enhancing compound selected from the group of magnesium sulfate, magnesium chloride, magnesium glycinate, and chelated forms of magnesium.

36. The method of treatment according to claim 35, further comprising the following step:
Administering a therapeutic dose of cystine.
37. The method of treatment according to claim 36, further comprising the following step:
Administering a therapeutic dose of selenium.
38. The method of treatment according to claim 37, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
39. The method according to claim 38, further comprising the following step:
Administering a therapeutic dose of Vitamin E.
40. The method of treatment according to claim 39, further comprising:
Administering a therapeutic dose of lipoic acid.
41. A method of treatment of neurodegenerative conditions, including to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia, comprising the following steps:
administering a selective COX-2 inhibitor;
administering a pharmaceutically acceptable magnesium enhancing compound selected from the group of magnesium sulfate, magnesium chloride, magnesium glycinate, and chelated forms of magnesium; and .
administering a therapeutic dose of cystine.
42. The method of treatment according to claim 36, further comprising the following step:
Administering a therapeutic dose of selenium.
43. The method of treatment according to claim 37, further comprising the following step:
Administering a therapeutic dose of Vitamin C.
44. The method according to claim 38, further comprising the following step:
Administering a therapeutic dose of Vitamin E.

45. The method of treatment according to claim 39, further comprising:
Administering a therapeutic dose of lipoic acid.
46. A method of manufacturing a treatment for treatment of conditions exhibiting inflammatory characteristics including viral disease, atherosclerosis, vascular disease, HIV, neurodegenerative conditions, and cancer, comprising:
combining a selective COX-2 inhibitor and cystine in a single dose formulation.
47. A method of manufacturing a treatment for treatment of conditions exhibiting inflammatory characteristics including viral disease, atherosclerosis, vascular disease, HIV, neurodegenerative conditions, and cancer, comprising:
combining a selective COX-2 inhibitor, cystine, and an HMG-CoA reductase inhibitor in a single dose formulation.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 September 2002 (06.09.2002)

PCT

(10) International Publication Number
WO 02/067853 A3

- (51) International Patent Classification⁷: A61K 31/34, 31/35, 31/195, 31/225, 31/355
- (21) International Application Number: PCT/US02/02480
- (22) International Filing Date: 26 January 2002 (26.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|----------------|-------------------------------|----|
| 60/264,511 | 26 January 2001 (26.01.2001) | US |
| 60/264,504 | 26 January 2001 (26.01.2001) | US |
| 60/307,689 | 25 July 2001 (25.07.2001) | US |
| 09/912,703 | 25 July 2001 (25.07.2001) | US |
| PCT/US01/31328 | 6 October 2001 (06.10.2001) | US |
| 09/997,490 | 17 November 2001 (17.11.2001) | US |
- (31) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- | | |
|----------|-------------------------------|
| US | 60/238,504 (CIP) |
| Filed on | 6 October 2000 (06.10.2000) |
| US | 60/238,506 (CIP) |
| Filed on | 6 October 2000 (06.10.2000) |
| US | 60/243,901 (CIP) |
| Filed on | 27 October 2000 (27.10.2000) |
| US | 60/243,902 (CIP) |
| Filed on | 27 October 2000 (27.10.2000) |
| US | 60/245,592 (CIP) |
| Filed on | 17 November 2000 (17.11.2000) |
| US | 60/264,511 (CIP) |
| Filed on | 26 January 2001 (26.01.2001) |
| US | 60/264,504 (CIP) |
| Filed on | 26 January 2001 (26.01.2001) |
| US | 60/307,689 (CIP) |
| Filed on | 25 July 2001 (25.07.2001) |
| US | 09/912,703 (CIP) |
| Filed on | 25 July 2001 (25.07.2001) |
| US | 09/997,490 (CIP) |
| Filed on | 17 November 2001 (17.11.2001) |
| US | PCT/US01/31328 (CIP) |
| Filed on | 6 October 2001 (06.10.2001) |
- (71) Applicant (for all designated States except US): PRO-BIOCHEM, LLC [US/US]; 326 Hedgepocket Way, Reisterstown, MD 21136 (US).
- (72) Applicants and Inventors: KINDNESS, George [GB/US]; 7207 Stonebrook Ct., Middletown, OH 45044 (US). SCHUMM, Brooke, III [US/US]; 2813 Thornbrook Road, Ellicott City, MD (US). GUILFORD, Timothy, F. [US/US]; 829 Forest Ave., Palo Alto, CA (US).
- (74) Agent: SCHUMM, Brooke, III; Daneker, McIntire, Schumm et al, Suite 800, 210 N. Charles St., Baltimore, MD 21201 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
31 October 2002

[Continued on next page]

WO 02/067853 A3

(54) Title: A COMBINATION AND METHOD OF TREATMENT OF HIV AND VIRAL DISEASES, VASCULAR DISEASE AND CANCER UTILIZING A COX-2 INHIBITOR AND CYSTINE

(57) Abstract: The inventors propose the combination of a selective COX-2 inhibitor and cystine first, for the treatment of anti-viral diseases, including HIV, immuno-compromised individuals, AIDS and hepatitis C; second, for the treatment of atherosclerosis and related atherosclerosis vascular disease states, coronary ischemic syndrome, thrombosis, and related vascular problems (atherosclerosis and these latter problems collectively referred to as "vascular-associated disease"), third, for the treatment of cancer and fourth, to alleviate 5-hydroxy tryptamine (5-HT) mediated mechanisms by at least relieving inflammatory symptoms, through regulation of cytokine activated responses, including migraine and migraine-like conditions, and to ameliorate neurodegenerative diseases aggravated by inflammatory condition and carotidynia. An HMG-CoA reductase inhibitor may be added to enhance the combination. Magnesium sulfate or similar compound is proposed to be added to enhance the treatment of neurodegenerative conditions.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US02/02480

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(7) : A61K 31/34, 31/35, 31/195, 31/225, 31/355 US CL : 514/451, 458, 460, 474, 548, 568 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/451, 458, 460, 474, 548, 568																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A,P	US 6,136,804 A (NICHTBERGER) 24 October 2000 (24.10.00), see the entire document.	1-47																		
A,P	US 6,218,369 B1 (BOMBARDELLI et al.) 17 April 2001 (17.01.01), see the entire document.	1-47																		
A,P	US 6,245,797 B1 (WINOKUR) 12 June 2001 (12.06.01), see the entire document.	1-47																		
A,E	US 2002/0094977 A1 (ROBL et al.) 18 July 2002 (18.07.02), see the entire document.	1-47																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"I"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"B" earlier document published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"G"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"I"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"I"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 11 AUGUST 2002		Date of mailing of the international search report 05 SEP 2002																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RAYMOND J. HENLEY III Telephone No. (703) 308-1235																		

THIS PAGE BLANK (USPTO)